WO2008076853A2 - Cardiac device and methods of use thereof - Google Patents
Cardiac device and methods of use thereof Download PDFInfo
- Publication number
- WO2008076853A2 WO2008076853A2 PCT/US2007/087497 US2007087497W WO2008076853A2 WO 2008076853 A2 WO2008076853 A2 WO 2008076853A2 US 2007087497 W US2007087497 W US 2007087497W WO 2008076853 A2 WO2008076853 A2 WO 2008076853A2
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- ventricle
- ribs
- heart
- wall
- diastolic
- Prior art date
Links
- 238000000034 method Methods 0.000 title claims abstract description 103
- 230000000747 cardiac effect Effects 0.000 title claims abstract description 21
- 230000003205 diastolic effect Effects 0.000 claims abstract description 163
- 210000002216 heart Anatomy 0.000 claims abstract description 124
- 230000002861 ventricular Effects 0.000 claims abstract description 74
- 239000012528 membrane Substances 0.000 claims abstract description 50
- 230000003247 decreasing effect Effects 0.000 claims abstract description 36
- 230000007423 decrease Effects 0.000 claims abstract description 24
- 230000035487 diastolic blood pressure Effects 0.000 claims abstract description 15
- 230000033001 locomotion Effects 0.000 claims abstract description 9
- 238000000638 solvent extraction Methods 0.000 claims description 32
- 210000005240 left ventricle Anatomy 0.000 claims description 28
- 208000005907 mitral valve insufficiency Diseases 0.000 claims description 20
- 230000003111 delayed effect Effects 0.000 claims description 9
- 238000007634 remodeling Methods 0.000 claims description 9
- 230000007246 mechanism Effects 0.000 claims description 6
- 238000004873 anchoring Methods 0.000 claims description 5
- 230000003190 augmentative effect Effects 0.000 claims description 5
- 230000000670 limiting effect Effects 0.000 claims description 5
- 230000008093 supporting effect Effects 0.000 claims description 4
- 238000007789 sealing Methods 0.000 claims 4
- 206010019280 Heart failures Diseases 0.000 abstract description 14
- 210000004379 membrane Anatomy 0.000 description 37
- 239000007943 implant Substances 0.000 description 30
- 238000002513 implantation Methods 0.000 description 30
- 206010052337 Diastolic dysfunction Diseases 0.000 description 20
- 230000006870 function Effects 0.000 description 19
- 210000001519 tissue Anatomy 0.000 description 17
- 210000004165 myocardium Anatomy 0.000 description 16
- 239000000463 material Substances 0.000 description 11
- 230000006872 improvement Effects 0.000 description 9
- 238000009434 installation Methods 0.000 description 9
- 210000005242 cardiac chamber Anatomy 0.000 description 8
- 208000010125 myocardial infarction Diseases 0.000 description 7
- 230000036961 partial effect Effects 0.000 description 7
- 230000000472 traumatic effect Effects 0.000 description 7
- 230000006835 compression Effects 0.000 description 6
- 238000007906 compression Methods 0.000 description 6
- 230000010339 dilation Effects 0.000 description 6
- 230000001747 exhibiting effect Effects 0.000 description 6
- 238000005259 measurement Methods 0.000 description 6
- 238000005192 partition Methods 0.000 description 6
- 208000024891 symptom Diseases 0.000 description 6
- 206010071436 Systolic dysfunction Diseases 0.000 description 5
- 229910045601 alloy Inorganic materials 0.000 description 5
- 239000000956 alloy Substances 0.000 description 5
- 239000008280 blood Substances 0.000 description 5
- 210000004369 blood Anatomy 0.000 description 5
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 5
- 210000004115 mitral valve Anatomy 0.000 description 5
- 210000005241 right ventricle Anatomy 0.000 description 5
- 230000008901 benefit Effects 0.000 description 4
- 230000008859 change Effects 0.000 description 4
- 230000000142 dyskinetic effect Effects 0.000 description 4
- 238000002592 echocardiography Methods 0.000 description 4
- 208000019622 heart disease Diseases 0.000 description 4
- 230000001976 improved effect Effects 0.000 description 4
- 230000002107 myocardial effect Effects 0.000 description 4
- 230000001338 necrotic effect Effects 0.000 description 4
- 229910001000 nickel titanium Inorganic materials 0.000 description 4
- 210000003540 papillary muscle Anatomy 0.000 description 4
- 230000002093 peripheral effect Effects 0.000 description 4
- 230000008569 process Effects 0.000 description 4
- 230000009467 reduction Effects 0.000 description 4
- 208000000059 Dyspnea Diseases 0.000 description 3
- 206010013975 Dyspnoeas Diseases 0.000 description 3
- 206010030124 Oedema peripheral Diseases 0.000 description 3
- 230000009471 action Effects 0.000 description 3
- 239000002131 composite material Substances 0.000 description 3
- 230000006378 damage Effects 0.000 description 3
- 238000003745 diagnosis Methods 0.000 description 3
- 201000010099 disease Diseases 0.000 description 3
- 230000000694 effects Effects 0.000 description 3
- 210000001174 endocardium Anatomy 0.000 description 3
- 210000002837 heart atrium Anatomy 0.000 description 3
- 230000004217 heart function Effects 0.000 description 3
- 230000000004 hemodynamic effect Effects 0.000 description 3
- -1 ischemia or hypoxia Chemical class 0.000 description 3
- 229920000139 polyethylene terephthalate Polymers 0.000 description 3
- 239000005020 polyethylene terephthalate Substances 0.000 description 3
- 230000002035 prolonged effect Effects 0.000 description 3
- 238000004088 simulation Methods 0.000 description 3
- 238000011477 surgical intervention Methods 0.000 description 3
- 238000012360 testing method Methods 0.000 description 3
- 206010007559 Cardiac failure congestive Diseases 0.000 description 2
- 206010048858 Ischaemic cardiomyopathy Diseases 0.000 description 2
- 206010067171 Regurgitation Diseases 0.000 description 2
- 230000002411 adverse Effects 0.000 description 2
- 210000001765 aortic valve Anatomy 0.000 description 2
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 2
- 230000008602 contraction Effects 0.000 description 2
- 230000003292 diminished effect Effects 0.000 description 2
- 208000035475 disorder Diseases 0.000 description 2
- 239000002934 diuretic Substances 0.000 description 2
- 229940030606 diuretics Drugs 0.000 description 2
- 230000004064 dysfunction Effects 0.000 description 2
- 230000002708 enhancing effect Effects 0.000 description 2
- 230000000302 ischemic effect Effects 0.000 description 2
- 230000007774 longterm Effects 0.000 description 2
- 230000005226 mechanical processes and functions Effects 0.000 description 2
- 230000010016 myocardial function Effects 0.000 description 2
- 229910052760 oxygen Inorganic materials 0.000 description 2
- 239000001301 oxygen Substances 0.000 description 2
- 230000000149 penetrating effect Effects 0.000 description 2
- 239000011148 porous material Substances 0.000 description 2
- 108090000765 processed proteins & peptides Proteins 0.000 description 2
- 238000005086 pumping Methods 0.000 description 2
- 230000002829 reductive effect Effects 0.000 description 2
- 230000001105 regulatory effect Effects 0.000 description 2
- 230000003014 reinforcing effect Effects 0.000 description 2
- 230000002441 reversible effect Effects 0.000 description 2
- 230000033764 rhythmic process Effects 0.000 description 2
- 238000012546 transfer Methods 0.000 description 2
- 230000001960 triggered effect Effects 0.000 description 2
- 229940124549 vasodilator Drugs 0.000 description 2
- 239000003071 vasodilator agent Substances 0.000 description 2
- 230000037303 wrinkles Effects 0.000 description 2
- 239000005541 ACE inhibitor Substances 0.000 description 1
- 101800000407 Brain natriuretic peptide 32 Proteins 0.000 description 1
- 206010056370 Congestive cardiomyopathy Diseases 0.000 description 1
- 201000010046 Dilated cardiomyopathy Diseases 0.000 description 1
- 229920000544 Gore-Tex Polymers 0.000 description 1
- 206010020880 Hypertrophy Diseases 0.000 description 1
- 206010021143 Hypoxia Diseases 0.000 description 1
- 206010061216 Infarction Diseases 0.000 description 1
- 206010027727 Mitral valve incompetence Diseases 0.000 description 1
- 206010028604 Myocardial rupture Diseases 0.000 description 1
- 239000004677 Nylon Substances 0.000 description 1
- 229910019142 PO4 Inorganic materials 0.000 description 1
- 102000035195 Peptidases Human genes 0.000 description 1
- 108091005804 Peptidases Proteins 0.000 description 1
- 239000004743 Polypropylene Substances 0.000 description 1
- 239000004365 Protease Substances 0.000 description 1
- 229910001069 Ti alloy Inorganic materials 0.000 description 1
- 230000007488 abnormal function Effects 0.000 description 1
- 230000004913 activation Effects 0.000 description 1
- 230000001154 acute effect Effects 0.000 description 1
- 239000000853 adhesive Substances 0.000 description 1
- 230000001070 adhesive effect Effects 0.000 description 1
- 238000002583 angiography Methods 0.000 description 1
- 229940044094 angiotensin-converting-enzyme inhibitor Drugs 0.000 description 1
- 238000005452 bending Methods 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 230000003185 calcium uptake Effects 0.000 description 1
- 238000004364 calculation method Methods 0.000 description 1
- 210000004413 cardiac myocyte Anatomy 0.000 description 1
- 238000012669 compression test Methods 0.000 description 1
- 238000010276 construction Methods 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- 238000013461 design Methods 0.000 description 1
- 238000006073 displacement reaction Methods 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 230000002526 effect on cardiovascular system Effects 0.000 description 1
- 229920000295 expanded polytetrafluoroethylene Polymers 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 239000000835 fiber Substances 0.000 description 1
- 238000002594 fluoroscopy Methods 0.000 description 1
- 230000007954 hypoxia Effects 0.000 description 1
- 230000001771 impaired effect Effects 0.000 description 1
- 238000010348 incorporation Methods 0.000 description 1
- 230000001939 inductive effect Effects 0.000 description 1
- 230000007574 infarction Effects 0.000 description 1
- 208000014674 injury Diseases 0.000 description 1
- 230000000297 inotrophic effect Effects 0.000 description 1
- 239000004041 inotropic agent Substances 0.000 description 1
- 230000003993 interaction Effects 0.000 description 1
- 208000028867 ischemia Diseases 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 238000002483 medication Methods 0.000 description 1
- 230000002503 metabolic effect Effects 0.000 description 1
- 229910052751 metal Inorganic materials 0.000 description 1
- 239000002184 metal Substances 0.000 description 1
- 229910001092 metal group alloy Inorganic materials 0.000 description 1
- 150000002739 metals Chemical class 0.000 description 1
- 239000000203 mixture Substances 0.000 description 1
- 238000012544 monitoring process Methods 0.000 description 1
- 230000010117 myocardial relaxation Effects 0.000 description 1
- 239000000712 neurohormone Substances 0.000 description 1
- HLXZNVUGXRDIFK-UHFFFAOYSA-N nickel titanium Chemical compound [Ti].[Ti].[Ti].[Ti].[Ti].[Ti].[Ti].[Ti].[Ti].[Ti].[Ti].[Ni].[Ni].[Ni].[Ni].[Ni].[Ni].[Ni].[Ni].[Ni].[Ni].[Ni].[Ni].[Ni].[Ni] HLXZNVUGXRDIFK-UHFFFAOYSA-N 0.000 description 1
- 150000002823 nitrates Chemical class 0.000 description 1
- 235000015097 nutrients Nutrition 0.000 description 1
- 229920001778 nylon Polymers 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 230000001575 pathological effect Effects 0.000 description 1
- 230000007170 pathology Effects 0.000 description 1
- 210000003516 pericardium Anatomy 0.000 description 1
- 235000021317 phosphate Nutrition 0.000 description 1
- 150000003013 phosphoric acid derivatives Chemical class 0.000 description 1
- 239000004033 plastic Substances 0.000 description 1
- 229920003023 plastic Polymers 0.000 description 1
- 229920000728 polyester Polymers 0.000 description 1
- 229920001155 polypropylene Polymers 0.000 description 1
- 238000003825 pressing Methods 0.000 description 1
- 108010008064 pro-brain natriuretic peptide (1-76) Proteins 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 238000011002 quantification Methods 0.000 description 1
- 230000008439 repair process Effects 0.000 description 1
- 239000012858 resilient material Substances 0.000 description 1
- 230000004044 response Effects 0.000 description 1
- 210000001908 sarcoplasmic reticulum Anatomy 0.000 description 1
- 231100000241 scar Toxicity 0.000 description 1
- 238000004904 shortening Methods 0.000 description 1
- 239000003195 sodium channel blocking agent Substances 0.000 description 1
- 229910001220 stainless steel Inorganic materials 0.000 description 1
- 239000010935 stainless steel Substances 0.000 description 1
- 238000011301 standard therapy Methods 0.000 description 1
- 230000000638 stimulation Effects 0.000 description 1
- 238000006467 substitution reaction Methods 0.000 description 1
- 230000004083 survival effect Effects 0.000 description 1
- 208000019270 symptomatic heart failure Diseases 0.000 description 1
- 230000035488 systolic blood pressure Effects 0.000 description 1
- 238000009864 tensile test Methods 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 210000000115 thoracic cavity Anatomy 0.000 description 1
- 230000008733 trauma Effects 0.000 description 1
- 238000011144 upstream manufacturing Methods 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61N—ELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
- A61N1/00—Electrotherapy; Circuits therefor
- A61N1/02—Details
- A61N1/04—Electrodes
- A61N1/05—Electrodes for implantation or insertion into the body, e.g. heart electrode
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
- A61B17/00—Surgical instruments, devices or methods, e.g. tourniquets
- A61B17/12—Surgical instruments, devices or methods, e.g. tourniquets for ligaturing or otherwise compressing tubular parts of the body, e.g. blood vessels, umbilical cord
- A61B17/12022—Occluding by internal devices, e.g. balloons or releasable wires
- A61B17/12099—Occluding by internal devices, e.g. balloons or releasable wires characterised by the location of the occluder
- A61B17/12122—Occluding by internal devices, e.g. balloons or releasable wires characterised by the location of the occluder within the heart
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
- A61B17/00—Surgical instruments, devices or methods, e.g. tourniquets
- A61B17/12—Surgical instruments, devices or methods, e.g. tourniquets for ligaturing or otherwise compressing tubular parts of the body, e.g. blood vessels, umbilical cord
- A61B17/12022—Occluding by internal devices, e.g. balloons or releasable wires
- A61B17/12131—Occluding by internal devices, e.g. balloons or releasable wires characterised by the type of occluding device
- A61B17/12168—Occluding by internal devices, e.g. balloons or releasable wires characterised by the type of occluding device having a mesh structure
- A61B17/12172—Occluding by internal devices, e.g. balloons or releasable wires characterised by the type of occluding device having a mesh structure having a pre-set deployed three-dimensional shape
Definitions
- Heart failure is one of the most common causes of in-hospital mortality for patients with cardiac diseases. Heart failure is typified by the inability of the heart to pump enough blood to meet the body's metabolic requirements for oxygen and nutrients leading to discrepancies between myocardial oxygen supply and demand.
- the left ventricle's inability to generate sufficient cardiac output i.e. HF
- HF left ventricular systolic
- its symptoms may also arise as a result of diastolic (filling of left ventricular chamber) dysfunction (with or without the presence of systolic dysfunction).
- diastolic dysfunction refers to changes in ventricular diastolic properties that have an adverse effect on ventricular diastolic pressures and ventricular filling.
- Intervention to alleviate the resultant symptoms of the physical changes described above may offer great benefit to patients with heart disease.
- Administration of vasodilators, diuretics, sodium channel blockers, and inotropic agents have been used to reduce the number of acute events and slow the advance of disease, but cannot reverse the physical changes to the heart.
- Surgical intervention can reduce the volume of the ventricle such that cardiac function is improved but carries high risk for the patient.
- Other less invasive modes of intervention offer improved function while reducing risk for the patient during and after the procedure.
- the present invention is directed to methods for the treatment of a patient's heart having, or one which is susceptible to, heart failure, in particular, a patient's heart exhibiting diastolic dysfunction.
- the diastolic dysfunction may be a result of one or more conditions, for example, reduced elastic recoil in the ventricular chamber, more specifically the left ventricle.
- Diastolic dysfunction is established, for example, by measurements of various echocardiographic parameters such as decreased peak filling velocity and prolonged relaxation time, signs of increased filling pressure, and clinical symptoms of dyspnea and peripheral edema.
- a diastolic recoil device which includes a membrane, a hub, preferably centrally located on the diastolic recoil device, and a radially expandable reinforcing frame formed of a plurality of ribs.
- ribs there may be at least 3 and up to 20 ribs, depending on the application.
- An elastic, resilient frame may be used.
- the ribs have distal ends which may be pivotally mounted to the hub and biased outwardly or fixed to the hub, and free proximal ends which are configured to curve or flare away from a center line axis upon expansion of the partitioning device.
- Tissue penetrating proximal anchors of the free proximal ends are configured to penetrate the tissue lining at an angle 30-120 degrees to the ccnterline axis of the diastolic recoil device.
- the tissue penetrating proximal anchors of the ribs may be provided with barbs, hooks, and the like which prevent undesired withdrawal of the tips from the heart wall.
- the diastolic recoil device and its components may be made with various sizes and diameters.
- the unconstrained diameter (D, in Figure 1) of the diastolic recoil device may be about 40mm to about 100 mm, and the height of the device when expanded (H, in Figure 1) may range from about 10mm to about 60mm, and when collapsed, the diastolic recoil device of any size will fit within a catheter of less than 12 mm for delivery.
- the unconstrained diameter of the diastolic recoil device is chosen to be oversized in relationship to the diameter of the ventricle that it is installed within.
- a single strand extends around essentially the entire periphery of the membrane so that the flexible periphery of the membrane between each pair of ribs is effectively sealed against the heart wall.
- the hub may have a distally extending stem with a non-traumatic support component.
- the distally extending stem with non-traumatic support component together may extend a variable distance from the base of the hub.
- the stem may extend from about 2mm to 20mm from the hub to space the central hub a selected distance from the wall of the ventricle where the diastolic recoil device is seated.
- the stem distance can be varied while retaining the same diameter membrane, thus permitting variable partitioning of the volume of the chamber.
- the support component has a plurality of pods or feet, e.g., at least three, or any number desired to distribute the force of the diastolic recoil device about a region of the ventricular wall surface to minimize, and preferably avoid immediate or long term damage to the tissue of the heart wall, by partitioning necrotic tissue such as tissue of a myocardial infarct (MI), or supporting weakened cardiac wall, and the like.
- necrotic tissue such as tissue of a myocardial infarct (MI), or supporting weakened cardiac wall, and the like.
- a diastolic recoil device adapted for percutaneous delivery to a ventricle of a heart of a patient comprising a plurality of radially expandable ribs connected at their distal ends to a central hub, is implanted in the ventricle of the patient wherein the radially expandable ribs are adapted to provide elastic support between opposing ventricular walls.
- a diastolic recoil device adapted for percutaneous delivery to a ventricle of a heart of a patient comprising a plurality of radially expandable ribs coupled at their distal ends to a central hub is implanted in the ventricle, wherein the ribs are adapted to augment ventricular wall movement during diastole.
- a diastolic recoil device adapted for percutaneous delivery to a ventricle of a heart of a patient comprising a plurality of radially expandable resilient ribs connected at their distal ends to a central hub and one or more anchor elements at each of the proximal ends of the ribs are adapted to secure the device to a selected area of a wall within the ventricle, wherein the ribs are adapted to support the wall and unload the cardiomyocytes to limit remodeling of the heart.
- a diastolic recoil device adapted for percutaneous delivery to a ventricle of a heart of a patient comprising a plurality of radially expandable ribs connected at their distal ends to a central hub is implanted in a patient, wherein the ribs are adapted to reduce diastolic pressure of a ventricle of the heart once deployed.
- a diastolic recoil device adapted for percutaneous delivery to a heart of a patient comprising a plurality of radially expandable ribs connected at their distal ends to a central hub; and a plurality of anchor elements attached to a plurality of said ribs at their proximal ends wherein the anchor elements are adapted to secure the apparatus to a wall of a ventricle of said heart; and, wherein once the device is implanted in a ventricle of a patient, the device is adapted to reduce a volume of the ventricle to improve the pressure- volume relationship of the ventricle.
- a diastolic recoil device comprising a resiliently deformable member and a plurality of anchors, is delivered percutancously to and anchored within the interior of a ventricle of a patient's heart to span a region of said ventricle, wherein the resiliently deformable member deforms from a first shape to a second shape during systole and to return to the first shape during diastole to assist in expansion of the ventricle.
- a diastolic recoil device comprising a resiliently deformable member and a plurality of anchors, is delivered pcrcutaneously to and anchored within the interior of a ventricle of a patient's heart to span a region of the ventricle, where the resiliently deformable member stores energy during systole and releases stored energy back to a wall of the ventricle in synchrony with a heart cycle.
- a diastolic recoil device further comprises a delayed release spring having cither a damped expansion mode or a triggered release such that the release of recoil forces back to the walls of the ventricular chamber can be selectively timed during diastole. This may aid individuals who require additional force to be applied back to ventricular walls during differing portions of diastole.
- a patient may be treated who has no systolic dysfunction, but does have diastolic dysfunction.
- Devices and methods arc provided which utilize a diastolic recoil device having a frame and a hub which can provide force back to the walls of the ventricle.
- the device does not have a membrane as partitioning a portion of the ventricle may not be necessary for these patients.
- the frame may need differing characteristics to perform, as these patients may require more force to be applied to potentially stiffened and thickened heart walls.
- the number of ribs may be increased, the thickness of the ribs may be increased, the stiffness of the ribs may be increased, or the type of alloys or composite of which the frame is made may be different from other devices provided for in this invention.
- the device may be seated lower than the base of the papillary muscles in the ventricle.
- the unconstrained diameter of such a device may be at least about 25mm to about 90mm.
- methods which include partitioning a chamber (e.g., left and/or right ventricles) of a patient's heart, exhibiting diastolic dysfunction disorder, or one which exhibits the characteristics of diastolic dysfunction, into a functional portion and an excluded, nonfunctional portion by implanting a diastolic recoil device according to the present invention.
- a chamber e.g., left and/or right ventricles
- Some embodiments of the invention includes the use of a diastolic recoil device having a partitioning membrane, preferably a reinforced partitioning membrane, with a pressure receiving surface, preferably concave, which defines in part the functional portion of the partitioned heart chamber when implanted or anchored within the patient's heart, in particular, within the ventricle.
- a patient suffering from a heart condition is treated by advancing percutaneously a collapsed diastolic recoil device comprising a plurality of radially expandable ribs connected at their distal ends to a central hub and having an anchor element at the proximal end of each of the ribs; expanding the ribs in a ventricle of the heart; and, securing the device to a selected area of a wall of the ventricle with the anchor elements thereby providing elastic support between opposing ventricular walls.
- the ribs thus absorbing and releasing recoil forces back to the area of attachment reduce forces directed at the area of the heart in the newly created nonfunctional portion of the ventricle. This reduction eases pressure on a weakened area of a cardiac wall of the nonfunctional portion of the chamber.
- the storing and release of energy by the frame occurs in synchrony with the action of the heart.
- This transfer of energy may decrease the ventricular pressure in diastole, increase the atrio- ventricular pressure gradient, increase filling, and thus improve ejection fraction
- Dyskinetic or aneurystic ventricular walls result in dyssynchronous behavior during the cardiac cycle, leading to inefficient pumping function.
- Installation of a device of the invention can remove those dyssynchronous contributions to heart rhythms, restoring overall synchrony in the cardiac cycle, and thus improve ejection fraction.
- a patient suffering from a heart condition is treated by advancing percutaneously a collapsed diastolic recoil device comprising a plurality of radially expandable ribs connected at their distal ends to a central hub and having an anchor element at the proximal end of each of the ribs; expanding the ribs in a ventricle of the heart; and, securing the device to a selected area of a wall of the chamber with the anchor elements thereby augmenting a ventricular wall movement during diastole.
- Another embodiment of the method treats a patient suffering from a heart condition by advancing percutaneously a collapsed diastolic recoil device with a plurality of radially expandable resilient ribs connected at their distal ends to a central hub, and an anchor element at the proximal end of each of the ribs; expanding the ribs in a ventricle of the heart; and, securing the device to a selected area of a wall of the ventricle with the anchor elements wherein the ribs support the ventricular wall, unloading the myocardium, decreasing stress and thus benefiting mechanical function. More efficient function and decreased stress leads to decreased rates of dilation, and hence may limit remodeling of the heart.
- Still another method of the invention treats a heart of a patient by advancing percutaneously a collapsed diastolic recoil device comprising a plurality of radially expandable ribs connected at their distal ends to a central hub and having an anchor element at the proximal end of each of the ribs into a ventricle of the heart; expanding the ribs in the chamber of the heart; and, securing the device to a selected area of chamber wall with the anchor elements thereby reducing the diastolic pressure of the ventricle.
- a collapsed diastolic recoil device comprising a plurality of radially expandable ribs connected at their distal ends to a central hub and having an anchor element at the proximal end of each of the ribs; expanding the ribs in a ventricle of the heart; and, securing the device to a selected area of a wall of the ventricle with the anchor elements thereby reducing mitral valve regurgitation.
- Another embodiment of the invention is a method of treating a patient suffering from a heart condition by advancing percutaneously to the interior of a ventricle of the patient's heart a diastolic recoil device comprising a resiliently deformable member and a plurality of anchors; securing the device to opposing wall sections of the ventricle with the anchors; deforming the deformable member as the opposing wall sections move toward each other during systole; and providing a recoil force from the deformable member to the wall sections during diastole.
- Yet another embodiment is a method of treating a patient suffering from a heart condition by advancing percutaneously to the interior of a ventricle of the patient's heart a diastolic recoil device comprising a resiliently deformable member and a plurality of anchors; securing the diastolic recoil device to opposing wall sections of the ventricle with the anchors; storing energy within the deformable member as the opposing wall sections move toward each other during systole; and releasing energy from the deformable member to the wall sections during diastole.
- use of the diastolic recoil device or the methods of treatment results in improvement in the ejection fraction of the ventricle.
- the ejection fraction increase may be at least about 5% up to about 90%.
- use of the diastolic recoil device or the methods of treatment results in decreasing the left ventricle (LV) functional chamber by about 10% to 40%.
- use of the diastolic recoil device or the methods of treatment results in decreasing minimum LV pressure during diastole at least by about 5%.
- use of the diastolic recoil device or the methods of treatment results in decreasing end-diastolic pressure by at least about
- the diastolic recoil device may be installed according to the methods of the invention in about one hour.
- the implantation of the device according to the methods of the invention requires require periods of about 25 minutes under a fluoroscope to install the partitioning device.
- suitable diastolic recoil devices and methods may be used in the left or right ventricle or other heart chambers.
- the left ventricle end systolic volume index (LVESVI) of the patient is decreased at least by about 5%.
- NT-Pro-BNP NT-Pro-Brain Natriuretic Peptide
- NT-Pro-BNP is a regulatory peptide which is produced in the ventricle, and is related to the level of stress in myocardium.
- NT-Pro-BNP is decreased post-implant by at least about 10%.
- implantation of a partitioning device reverses the decline in ventricular function which may mitigate mitral valve regurgitation and/or decrease the stress on impaired valve leaflets sufficiently to alleviate regurgitation.
- Diastolic recoil device implantation according to this invention may therefore benefit patients with mitral valve regurgitation from any cause and decreases the regurgitant fraction by at least about 10%.
- Figure 1 is an elevational view of a partitioning device embodying features of the invention in an expanded configuration.
- Figure 2 is a plan view of the diastolic recoil device shown in Figure I illustrating the upper surface of the device.
- Figure 3 is a bottom view of a diastolic recoil device.
- Figure 4 is a perspective view of one embodiment of a non-traumatic tip of the distally extending stem of a diastolic recoil device.
- Figure 5 is an elevational view of a diastolic recoil device embodying an alternative support component of the invention in an expanded configuration.
- Figure 6 is a partial elevational view of a diastolic recoil device embodying an alternative support component with curved bumper shaped feet.
- Figure 7 is a partial elevational view of a diastolic recoil device embodying an alternative support component with J- shaped feet.
- FIG. 8 is a partial elevational view of a diastolic recoil device embodying an alternative support component with J- shaped feet.
- Figure 9 is a partial elevational view of a diastolic recoil device embodying an alternative support component with J- shaped feet.
- Figure 10 is a partial cross-sectional view of a lower section of a diastolic recoil device as shown in Figure 2 taken along the lines 212-212, showing details of connection of the ribs to the hub, the support component, and feet of a diastolic recoil device.
- Figure 11 is a detail cross sectional view of the hub of a diastolic recoil device as shown in Figure 10, taken along lines 1013-1013.
- Figure 12 is a plan view of a diastolic recoil device incorporating a delayed or damped spring release mechanism attached to the pressure bearing side of the frame of the device.
- FIG. 13 is a plan view of a diastolic recoil device which includes a frame and a hub but no membrane.
- Figure 14 is an elevational view of the device shown in Figure 13.
- Figure 15A is a partial elevational view of an alternate basal support for the device shown in Figures 13 and 14.
- Figure 15B is a partial elevational view of an alternate basal support for device shown in Figures 13 and 14.
- Figure 16A is a schematic view of a patient's heart exhibiting characteristics of heart failure or incipient CHF.
- Figure 16B is a schematic view of the patient's heart of Figure 16A after treatment according to a method of the present invention using a round shaped diastolic recoil device.
- Figure 17 is a schematic view of the patient's heart of Figure 16A after treatment according to a method of the present invention using an elliptical shaped diastolic recoil device.
- Figure 18A is a drawing of the echocardiograph image of the patient's heart after treatment according to a method of the present invention using a diastolic recoil device at end-diastole, highlighting the effective diameter of the diastolic recoil device in the relaxed state.
- Figure 18B is a drawing of the echocardiograph image of the patient's heart after treatment according to a method of the present invention using a diastolic recoil device at end-systole, highlighting the effective diameter of the diastolic recoil device in the constrained state.
- Figure 19 is a diagrammatical illustration of the elastic characteristics of an embodiment of a diastolic recoil device implant.
- Figure 20 is a schematic representation of a heart with a ventricle having two distinct regions of myocardium with different contractile properties, Region 1 and Region 2.
- Figures 21A-C are diagrammatical representations of the end-systolic pressure volume relationship (ESPVR) and end-diastolic pressure volume relationship (EDPVR) of the ventricle of Figure 20 prior to installation of a partitioning device.
- ESPVR end-systolic pressure volume relationship
- EDPVR end-diastolic pressure volume relationship
- Figure 22 is a schematic representation of a heart with a ventricle having two distinct regions after installation of a diastolic recoil device.
- Figures 23A-C are diagrammatical representations of the ESPVR.
- EDPVR of the ventricle of Figure 22 after treatment according to the present invention shows the comparison of the Stroke Volume, pre-implantation and post- implantation.
- Figure 24A is a diagrammatical illustration of the left ventricular pressure
- FIG. 24B is one diagrammatical illustration of the left ventricular pressure (LVP) of the ventricle of Figure 4A after treatment according to the present invention.
- LVP left ventricular pressure
- the present invention is directed to devices and methods for the treatment of a patient's organ such as a heart.
- the heart is susceptible to or experiencing diastolic dysfunction, mitral valve regurgitation or heart failure.
- Diastole is the phase of cardiac cycle during which relaxation of the heart muscles occurs after ejecting blood into general circulation and is governed by active and passive properties of the myocardium, geometrical characteristics of the chamber and external forces.
- left ventricular diastolic filling begins with opening of the mitral valve as pressure in the ventricle falls below pressure in the atrium. As the ventricle begins to contract the pressure in the ventricle soon exceeds that of the atrium and the mitral valve closes, which marks the end of diastole.
- the ventricular pressure and volume at this point are referred to as end-diastolic pressure ("EDP") and end- diastolic volume (“EDV”), and the beginning of ventricular systole.
- the rate and amount of left ventricular diastolic filling depends upon the positive pressure upstream of the left ventricle provided by venous return and decreasing pressure provided within the left ventricle by expansion of the ventricle during diastole.
- a reduction in ventricular compliance i.e., increase in stiffness of ventricular heart wall
- less ventricular filling i.e. decreased end-diastolic volume EDV
- a greater diastolic pressure resulting in a change in the ventricular diastolic pressure-volume characteristics.
- the left ventricular elastic recoil forces may be diminished, therefore leading to increase of the ventricular filling pressure.
- Diastolic dysfunction may also be caused by changes in the rate and degree of left ventricular relaxation, which as stated above, in part is an active process.
- Several factors can affect left ventricular relaxation, including inotropic stimulation, fast heart rates, non-uniform heart activation and altered timing of all the forces that oppose ventricular ejection. Since calcium uptake by the sarcoplasmic reticulum is energy- dependent, any process that decreases the availability of high-energy phosphates, such as ischemia or hypoxia, also impairs myocardial relaxation.
- Diastolic dysfunction is established, for example, by measurements of various echocardiographic parameters such as decreased peak filling velocity and prolonged relaxation time, signs of increased filling pressure and clinical symptoms of dyspnea and peripheral edema.
- the devices and methods herein can be used to treat a patient's heart suffering from a diastolic dysfunction disorder or a condition exhibiting the characteristics of diastolic dysfunction.
- the devices and methods herein involve implanting within the ventricle a device whose shape elastically distorts during systole and recoils during diastole to augment the ventricle's natural recoil action.
- the device also partitions the patient's ventricle into a functional portion and an excluded, non-functional portion.
- the method may be used to treat a heart, in particular the left ventricle, which is exhibiting signs of diastolic dysfunction. Diastolic dysfunction may evidence itself by portions of the chamber becoming dilated, dyskinetic or akinetic, depending on the particular pathology inducing damage to the heart.
- FIG. 1 illustrates a diastolic recoil device 130 which embodies features of the invention and which may be utilized in practicing the methods herein.
- the device 130 includes hub 132, preferably centrally located on the diastolic recoil device, and a radially expandable reinforcing frame 133 formed of a plurality of ribs 134 connected at their distal end to the hub.
- Alternative embodiments of the devices herein include at least three ribs.
- the ribs form an clastic frame and can be made of material such as, for example, Nitinol stainless steel, titanium alloys, NiTi alloy, other metal alloys, or plastic composites.
- the ribs/frame are made of a material which allows for compression of the free proximal ends towards the central axis during delivery and self expansion upon deployment (e.g. in the patient's heart).
- the ribs 134 have distal ends 136 which may be pivotally mounted to the hub 132 and biased outwardly or fixed to the hub, and free proximal ends 137 which are configured to curve or flare away from a center line axis 138 at least upon expansion of the diastolic recoil device.
- Proximal ends 137 of ribs 134 in their expanded configuration angle outwardly from the hub at an angle 0 of about 20- 90° away from a centerline axis 138 of the device.
- the free proximal ends 137 curve outwardly so that the membrane when secured to the ribs of the expanded frame forms a trumpet-shaped concave pressure receiving surface.
- Proximal ends 137 of ribs 134 can include anchors 150 configured to engage, and preferably penetrate into, the target tissue (e.g. endocardium of heart chamber to be partitioned, i.e. a ventricle). This enables the securing of a peripheral edge of the diastolic recoil device to the heart wall and fixation of the diastolic recoil device within the chamber so as to partition the chamber into two portions.
- Anchors 150 are configured to penetrate the tissue lining at an angle ranging from 30-120 degrees to the centerline axis 138 of the partitioning device. Anchors 150 can include barbs, hooks and the like which prevent undesired withdrawal of device 130 from the target tissue.
- a membrane 131 can be attached to the ribs 134 of the frame.
- membrane 131 can be made of a porous material, for example, expanded polytetralluoroethylene (ePTFE, or GORE-TEX®, one commercially available product) or a non-porous material. When membrane 131 is porous, it facilitates tissue ingrowth after deployment in the non-functional portion of the heart chamber. Membrane 131 can also be formed from other mesh materials including metals, alloys, or composites. In some cases Membrane 131 is formed from a biocompatible polymeric material such as nylon, polyethylene terephthalate (PET) or polyesters such as hytrel.
- PET polyethylene terephthalate
- hytrel polyesters
- the membrane 131 has a first layer secured to the concave face of the frame formed by the ribs 134, which creates a pressure receiving surface 135.
- the pressure receiving surface 135 is presented to the functional portion of the partitioned chamber.
- the membrane 131 may have a second layer secured to the convex face of the frame formed by the ribs 134, creating a non-pressure receiving surface 145.
- the non-pressure receiving surface 145 is presented to the non- functional portion of the partitioned chamber.
- the hub 132 shown in Figure 1 preferably has a distally extending stem
- the distally extending stem 143 with non-traumatic support component 144 together may extend a variable distance from the base of the hub 132, in order to space the device a selected distance from the wall of the chamber where the device is to be seated, thus permitting variable partitioning of the volume of the chamber.
- the stem 143 and support component 144 together may extend from about 3mm Io about 15mm from the central hub 132 to isolate differing proportions of the chamber or to provide suitable fits for differing size hearts.
- Diastolic recoil devices according to the present invention have several distinct configurations.
- the unconstrained con figuration is measured prior to any constriction or installation within a patient, and represents the largest diameter possible.
- the diameter (D) as shown in Figure 1 of a device in its unconstrained configuration is at least 35mm, up to about 100mm, and its height (H) is at least 10mm, to about 60mm, as needed to fit within the heart of a patient as more fully discussed below.
- a diastolic recoil device When in its collapsed configuration, a diastolic recoil device has a diameter of less than 12mm, such that it fits in a catheter for endovascular delivery.
- EDD End Diastole Diameter
- the diastolic recoil device implant is matched to the size of the left ventricle (e.g., the chamber into which it will be implanted) by comparing the left ventricle end-diastolic diameter at the level of the base of the papillary muscles ("landing zone" diameter) to the unconstrained diastolic recoil device diameter.
- the unconstrained diameter of the selected diastolic recoil device is oversized as compared to the diameter of the landing zone.
- the unconstrained diameter of the diastolic recoil device is selected to be oversized by at least about 10% up to about 60% over the diameter of the landing zone.
- the diastolic recoil device is elastic and its configuration changes from a small diameter at end-systole (ESD) to a larger diameter (EDD) at end-diastole.
- ESD end-systole
- EDD larger diameter
- the compression of the diastolic recoil device from end-diastolic to end-systolic configuration causes additional compressive forces to be stored in the elastic frame of the device and is preferably designed to be substantially equivalent at end systole to the clastic restoring forces that originate in the myocardium in a healthy heart.
- Figure 2 illustrates a top view of a diastolic recoil device 230 in its unconstrained configuration, as viewed from above the pressure receiving surface 235.
- the diastolic recoil device 230 of Figure 2 has ribs 234 which are radially expandable and connected at their distal end to a central hub.
- the ribs are adapted to provide an elastic recoil force to a wall of a chamber of a heart (e.g. a left or right ventricle).
- the ribs store energy during systole and release the stored energy back to the wall of the chamber of the heart in synchrony with the heart cycle.
- the device 230 further comprises a membrane 231 coupled to the radially expandable ribs 234.
- At least part of membrane 231 is secured to a pressure receiving side of the frame 233, creating the pressure receiving surface 235. Radial expansion of the free proximal ends 237 unfurls the membrane 231 secured to the frame 233 so that the membrane presents the pressure receiving surface 235 which defines the functional and nonfunctional portions of the chamber.
- a peripheral edge 239 of the membrane 231 may be serrated as shown in Figure 2. ⁇ serrated edge of peripheral edge 239 in this embodiment helps the membrane spread flat at the periphery.
- Anchors 250 can include barbs, hooks and the like which prevent undesired withdrawal of device 130 from the wall of the chamber of heart after implantation of the device 230.
- the ribs 234 may be individually of variable length and the membrane
- the membrane 231 may be of variable shape suitable to practice the present invention.
- the membrane 231 and frame 233 define a circular periphery and in other embodiments the membrane 231 and frame 233 define an eccentric or elliptical periphery.
- a strand 240 extends around essentially the entire periphery of the membrane so that the flexible periphery of the membrane between each pair of ribs 234 is effectively sealed against the heart wall.
- the effectiveness of the seal contributes to facile endothelialization of the pressure receiving surface of a porous membrane. Once endothelialized, the membrane supports regrowth of a new inner wall of the chamber.
- the expansive strand 240 is formed from material which is stifFer than the flexible, unsupported material of the membrane to provide an outward expansive force or thrust to prevent formation of undesirable inwardly directed folds or wrinkles when the ribs of the diastolic recoil device are in a contracted configuration.
- a suitable strand 240 is formed from materials such as polypropylene suture or super-elastic NiTi alloy wires. Such strands are typically about 0.005 to about 0.03 inch (about 0.13 to about 0.76 mm) in diameter to provide the requisite outward expansive force when placed in a circular position such as around the periphery of the membrane in less than completely expanded configuration. Ends 241 and 242 of the expansive strand 240 are shown extending away from the diastolic recoil device in Figure 2. The ends 241 and 242 may be left unattached or may be secured together, e.g. by a suitable adhesive, or to the membrane 231 itself.
- the outwardly biased strand 240 ensures that there are no inwardly directed folds or wrinkles and that none are formed when the device is expanded for deployment within the heart chamber.
- the strand 240 may be several strands of materials as above, rather than just one.
- FIG. 3 is a bottom view of a device 330 herein.
- the nonpressure receiving surface 345 of the membrane 331 which is secured to the ribs 334 (dotted lines) are illustrated in this view.
- Extending from the base of the frame 333 are feet 355 which support the device within the non-fijnctional portion of the chamber being partitioned against a wall therein.
- Feet 355 extend radially and preferably are interconnected by lateral supports 346 which help distribute the force over an expanded area of the surface of the chamber.
- Feet 355 and lateral supports 346 are made of resilient material which can support the device without causing trauma to the wall of the chamber at contact points. This minimizes or avoids immediate or long term damage to the tissue of the heart wall.
- the diastolic recoil device can be used to support weakened tissue of damaged heart wall such as necrotic tissue caused by myocardial infarction (MI) and the like.
- MI myocardial infarction
- Figure 4 is a side view of the support component of the device.
- the support component 444 has a plurality of feet 455, e.g., at least three or any variable number.
- the support component 444 atraumatically contacts the wall of the ventricle within the nonfunctional portion of the partitioned ventricle, and distributes direct pressure on the wall to minimize stress on the cardiac wall in the nonfunctional portion of the partitioned ventricle through the feet 455.
- Support component 444 comprises a stem coupled to a non-traumatic base structure such as the plurality of feet 455 and connected on its other extremity to the stem 443 which extends distally from the non- pressure receiving side of the frame of the device.
- the support component 444 can vary in length from about 3mm to about 12mm such that the non functional portion is sufficiently large in size/volume to partition necrotic tissue, such as tissue of a myocardial infarct (MI), a weakened cardiac wall, or the like.
- necrotic tissue such as tissue of a myocardial infarct (MI), a weakened cardiac wall, or the like.
- ⁇ web of material may extend between adjacent feet 445 to provide further support in addition to or in lieu of the supports 446.
- Figure 5 illustrates a diastolic recoil device 530 comprising a frame 533 with ribs 534.
- the membrane 531 is attached to the frame 533 and the anchors 537 contact the wall of the chamber to secure the device within the chamber in order to partition it.
- Device 530 has a nontraumatic support component 544 which has a simple rounded end which is connected to the stem 543.
- the stem 543 is connected to the central hub 532 which is connected to the frame 533.
- Figure 6 illustrates an alternative support component 644 for the devices of the invention.
- Support component 644 has a plurality of curved bumpers 645 which act as "feet" and contact the wall of the chamber atraumatically.
- FIG. 7 illustrates an alternative support component 744 which has feet such as the plurality of J- bumpers 745.
- Figure 8 illustrates a different embodiment of the support component 844 which has a plurality of J-shaped bumpers 845.
- Figure 9 illustrates another embodiment of the support component 944 which has a soft, non-traumatic coil 945 which contacts the wall of the heart chamber, and distributes the force from a diastolic recoil device to a larger area of the wall of the heart, reducing strain on weakened or necrotic areas of the chamber.
- This connector bar permits selective connection of the diastolic recoil device to a delivery catheter for delivery within the ventricle, selective placement of the device once within the ventricle to partition the ventricle, selective deployment of the partitioning device and selective release of the diastolic recoil device from the delivery catheter.
- Figure 10 also illustrates the connection between connector hub 1032, stem 1043, support component 1044, and feet 1045.
- a device 1230 further incorporating a delayed release spring 1260 as shown schematically in Figure 12, can be utilized to assist diastolic function.
- delayed response spring 1260 is attached to restraint struts 1261 which in turn releasably contact the frame 1233 on the non-pressure bearing side 1245 of the membrane 1231.
- the ventricle begins an unassisted expansion while the device is partially secured from freely expanding.
- the delayed release mechanism is triggered.
- the restraint struts are 1261 released from contact with the frame 1233, and the stored energy fully released at that point in the cardiac cycle.
- the majority of the recoil energy can be given back to the ventricular wall at a select point during diastole, as required for a particular patient.
- Another embodiment of this aspect of the invention may have a spring means including only a damped releasing mechanism.
- the subsequent contraction of the ventricle during systole re-engages the delayed release spring mechanism or restores the damped spring to restore the contact between the restraint struts 1261 and the frame 1233 when the frame is in the compressed state for further cycles of delayed recoil assistance to the ventricle.
- FIG. 13 has a frame 1333 and central hub 1332 as previously described, but which has no membrane.
- the resilient frame provides force back to the walls of the ventricle and improves the diastolic function of the heart.
- the frame may need to be different from the frames of other embodiments of this invention, i.e. frame 133 of Figure 1.
- the ventricles of this population of patients may require more force to be applied back to the ventricular walls, which may be thickened and stiffened relative to healthy ventricular walls. It may also be necessary to increase the number of ribs, the thickness of the material of the ribs, the relative stiffness of the ribs, and/or use different alloys or material compositions to form the frame in order to manufacture a device with appropriate resiliency/ stiffness properties.
- the device may seat lower in the ventricular chamber, and may thus require devices with smaller diameters relative to those used for patients with ventricular dilation. The size matching then is made for the end-diastolic diameter of a landing zone at a level further below the base of the papillary muscles.
- the unconstrained diameter of devices according to this embodiment of the invention may therefore be at least 25 mm up to about 90mm.
- the central hub 1432 as shown in the side elevation view of a device depicted in Figure 14, may not have any distal extension and may ends as a flat disk.
- a distal extension of hub 1432 may consist of a short rounded nub, or may connect to flexible basal supports which may stabilize the device in its seat in the apex of the ventricle.
- the basal supports may be configured in many ways. Two examples are given in Figures 15A and 15B respectively, shown as basal supports 1561 A and 1561B.
- Implantation of the devices herein can be accomplished endovascularly or intraoperatively in as little as one hour by a physician or appropriately trained personnel. Such implantation presents limited risk to the patient and requires the patient to be under a fluoroscope for a period of as little as 20 minutes.
- Implantation of the diastolic recoil device in the ischemic and enlarged ventricle may bring back the ability of the ventricle to store elastic energy during systole and return this energy in the form of elastic recoil forces during diastole.
- this return of energy in the form of elastic recoil may contribute to the improvement of the diastolic function, i.e., decrease of the filling pressure and increase in the magnitude of the early filling in patients with ischemic and/or dilated cardiomyopathy.
- the ejection fraction of the chamber is increased by at least about a 5% change.
- Diastolic recoil devices of the present invention are delivered percutaneously or intraoperatively.
- a suitable delivery device is described in co-pending application Serial No. 10/913,608, filed on August 5, 2004, entitled “Ventricular Partitioning Device", assigned to the assignee of the present invention, the full disclosure of which is incorporated herein by reference.
- the diastolic recoil devices may be conveniently formed by the method described in above-referenced co-pending application Serial No. 10/913,608 assigned to the assignee of the present invention and which is incorporated herein by reference in its entirely.
- Figure 16A is a schematic illustration of a patient's heart 1610 showing the right ventricle 161 1 and the left ventricle 1612 with the mitral valve 1613 and aortic valve 1614. A pericardium membrane 1615 is shown surrounding the heart 1610. Figure 16A illustrates a patient's heart with apical dilatation (round enlarged apex 1616 of the LV) which can be found in patients exhibiting characteristics of congestive heart failure.
- Figure 16B illustrates the left ventricle 1612 of Figure 16A after it has been partitioned, with a diastolic recoil device 1630 having features according to the present invention and as described further below, into a main functional or operational portion 1618 and a secondary, essentially non- functional portion 1617.
- Figure 17 is a schematic view of the patient's heart of Figure 16A after treatment according to a method of the present invention using an elliptical shaped diastolic recoil device 1730. The device 1730 is implanted into the left ventricle 1712 of the heart 1710, creating a functional portion 1718 and nonfunctional portion 1717.
- Figures 18A and 18B are drawings of echocardiograph images of a patient's heart at end-diastole, and end-systole, respectively.
- the contours of the diastolic recoil device implanted in the left ventricle are visible as fine white lines in the base of the ventricle. Portions of the ribs and periphery can be seen in Figures 18A and 18B.
- the diameter of the elastic diastolic recoil device is at its maximal implanted diameter (Figure 18A) at end-diastole, and at its minimal implanted diameter at end-systole ( Figure 18B).
- End-systolic diameters (ESD) can be in the range from about 25mm to about 55mm.
- End-diastolic diameters (EDD) can be in the range of about 45mm to about 70mm.
- the compression of the partitioning device from end-diastolic to end-systolic configuration causes elastic recoil forces to be stored in the elastic frame of the device, and to be transmitted to the myocardium during ventricular filling in the outward direction thus enhancing outward motion of the ventricular walls.
- This storing and release of energy by the frame occurs in synchrony with the action of the heart.
- This transfer of energy may decrease the ventricular pressure in diastole, increase the atrio-ventricular pressure gradient, increase filling, and thus improve ejection fraction
- Dyskinetic or aneurystic ventricular walls result in dyssynchronous behavior during the cardiac cycle, leading to inefficient pumping function.
- the partitioning device is substantially circular but another embodiment of the invention utilizes an elliptical shaped partitioning device as shown in Figure 17.
- Other configurations of the partitioning device are compatible with the construction as described above and with methods to partition a chamber of a heart as set forth here.
- the devices herein can be used to treat a patient suffering from a heart condition.
- Such heart conditions can include, for example, mitral valve regurgitation, myocardial infarction, or scar tissue or akinetic tissue in a heart chamber.
- a patient can be screened for treatment by the a devices herein by any means known in the art including, but not limited to, measurements of echocardiography parameters may be such as decreased peak filling velocity and prolonged relaxation time, signs of increased filling pressure, clinical symptoms of dyspnea and peripheral edema, as well as low ejection fraction and a distance a patient can walk in 6 minutes.
- the diastolic recoil device implant may be matched to the size of the chamber where it is to be inserted (e.g. left ventricle) when the device is to be inserted into the left ventricle this can be accomplished by comparing the left ventricle end-diastolic diameter at the level of the papillary muscles base. This diameter is referred to hereinafter as the landing zone diameter. Measurement of landing zone diameter may be made by any method known in the art including; echocardiography, fluoroscopy, PET, MRI, contrast angiography, and the like, the landing zone diameter is the compared to the relaxed deployed/device diameter.
- the ventricle When a device is to be implanted in a ventricle, the ventricle may be dilated such that its end diastolic diameter is greater than 45mm or even greater than 65mm. Jn some cases, to maximize the occurrence of a permanent seal between the implant and the endocardium, the relaxed diameter of the selected diastolic recoil device is oversized as compared to the diameter of the landing zone. The relaxed diameter of the device can be oversized by at least about 10% and up to 60% over the landing zone diameter.
- the diastolic recoil device implanted thus decreases the LV volume by at least about 10% up to about 40%.
- the ratio of the nonfunctional portion to the functional portion, created by partitioning the ventricle by a method of the invention is at least 1 :10 or up to about 1 :3.
- the diastolic recoil device frame is elastic and its diameter changes from a small diameter at end-systole to a larger diameter at end-diastole.
- the compression of the diastolic recoil device from end-diastolic to end-systolic configuration causes additional compressive forces to be stored in the elastic frame of the device, thus enhancing the ejection fraction of the chamber by at least about 10%, or up to about 90%.
- the elastic characteristics of the diastolic recoil device implant may be determined by a tensile/compression test, an example of which is diagrammatical Iy shown in Figure 19.
- the diastolic recoil device is positioned inside a custom designed fixture which was connected to a force transducer.
- the fixture was designed to create substantially equal compressive radial force (compatible and corresponding to physiological range of forces developed by normal myocardial fibers) on all ribs 34 (as described below) of the implant, thus determining the compression stress-diameter relationship for the frame 33 (as described below) of the device.
- Figure 19 shows an exemplary elastic property of the diastolic recoil device.
- the magnitude of the elastic recoil forces stored in the diastolic recoil device implant increases as the diastolic recoil device diameter decreases under compression.
- FIG. 20 is a schematic representation of a heart with dilation and poor function in the left ventricle, having two distinct regions of myocardium surrounding the interior of the ventricle. Region 1 represents normal myocardium and region 2 represents dilated and dyskinetic or akinetic/ myocardium.
- a simulation experiment is performed, using an elastance model, as described in J H. Artip; et al.; J.
- FIG. 21A-C represent a simulation carried out using a ventricle as in figure 20 without a partitioning device.
- the dashed lines labeled ESPVR End Systolic Pressure Volume Relationship
- EDPVR End Diastolic Pressure Volume Relationship
- the effect is modeled wherein the akinetic Region 2 of a ventricle with diastolic dysfunction (as shown in Figure 22) of the LV is partitioned by a partitioning device of the invention.
- the ESPVR and EDPVR for the individual contributions from normal Region 1 , the diastolic recoil device, and akinetic Region 2 are represented in Figures 23 A and B.
- the normal Region 1 now exhibits a steeper slope to its ESPVR as the diastolic recoil device isolates Region 2 from Region 1 , reducing the overall volume and conferring greater resistance as systole proceeds.
- FIG. 23B shows similar information as that in Figure 19, as it represents the performance of the diastolic recoil device as it is compressed, and the dashed line in Figure 23 B is the ESPVR/EDPVR curve for the akinetic Region 2 in Figure 22.
- the new ESPVR and EDPVR for the ventricle as a whole are shown in Figure 23C, as solid lines.
- the corresponding ESPVR and EDPVR for the pre-implant ventricle from Figure 21C are also reproduced in Figure 23C as dashed lines for comparison.
- the ESPVR and EDPVR curves of the post-implant ventricle are shifted leftwards as compared to the curves of the dilated pre-implant ventricle ( Figure 23C "ESPVR Pre- Implant” and "EDPVR Pre-implant", dashed lines).
- the ESPVR curve for the partitioned ventricle is shifted more than the EDPVR curve for the partitioned ventricle. This results in increased pump function of the ventricle which can be demonstrated by examining the resultant the pressure-volume loops.
- the stroke volume (SV) for the ventricle, pre-partitioned ( Figure 20) and partitioned ( Figure 22), are indicated by the shaded volumes labeled "SV Pre-implant” and "SV Implant".
- the stroke volume is represented by the width of these shaded volumes as filling proceeds along the EDVPR curves.
- the right-hand boundary of the stroke volume is the pressure/volume line at end diastole, when isovolumetric contraction begins, and the left-hand boundary is the volume/pressure line representing isovolumetric relaxation during the heart cycle.
- the partitioned ventricle exhibits increased stroke volume (SV) compared to the dilated, pre- implant ventricle with akinetic Region 2 at comparable end-diastolic and aortic pressures ("SV Implant” vs. "SV Pre-implant" in Figure 23C).
- FIGs 24A and 24B are diagrammatical illustrations of the recordings of the left ventricular pressure (LVP) in one dilated ventricle with diastolic dysfunction before and after implantation of a diastolic recoil device, respectively.
- LVP left ventricular pressure
- FIG. 24A diastolic dysfunction results in inefficient filling of the ventricle at relatively high mean diastolic pressure in the ventricle.
- the akinetic ventricle can neither compress nor expand as effectively as a normal ventricular chamber.
- the resultant filling pressure at early diastole is therefore higher than in a healthy heart and early filling is decreased.
- the device During installation of the diastolic recoil device, the device is anchored to functional portions of the ventricle wall, partitioning the akinetic (nonfunctional) portion of the chamber. This mode of attachment allows the elastic frame of the partitioning device to gain energy from the effectively contracting portion of the ventricular wall, by compressing the elaslically resilient frame. As the ventricle relaxes and expands, the energy stored in the frame is released and imparts additional recoil force back to the ventricle wall, which aids in the process of filling the ventricular chamber. As can be seen from Figures 24A and 24B, implantation of the diastolic recoil device resulted in decreased minimum diastolic pressures.
- the minimum LV pressure is decreased by at least 50% (contrasted by points A and A' in Figures 24A and 24B respectively) and mean diastolic pressure at least by 10%.
- the contribution of the elastic energy from the frame assisting expansion of the walls of the ventricle was observed in early diastole, thereby augmenting filling and normalizing diastolic pressure.
- Decreased mean diastolic pressure of the partitioned ventricle compared to that of the pre-implant ventricle indicates improved diastolic function (mean diastolic LVP of ca. 14mm Hg in Figure 24B vs. "mean diastolic LVP of ca. 22mm Hg in Figure 24A).
- the use of a diastolic recoil device and methods of the invention yields a decrease of minimum LV pressure during diastole by at least about 5% up to about 100%.
- the use of a diastolic recoil device by the methods of the invention yields a decrease of end-diastolic pressure by at least about 5%, and up to about 35%.
- LVESVI left ventricle end systolic volume index
- LVESVI indicates the size of the ventricle at end systole with values normalized to body size.
- the baseline value for a healthy individual is ⁇ 25ml/m 2 .
- LVESVI has significant predictive value for survival outcome, and may represent the most significant correlation used in diagnosis and treatment.
- a patient can be first diagnosed as having heart disease by determining or detecting in that patient a LVESVI greater than 60 ml/m 2 . Such patient is thus treated by implanting one or more of the devices herein.
- the diastolic recoil device by partitioning the ventricle into functional and non- functional portions, causes an initial decrease in LVESVI upon installation.
- the implantation of the diastolic recoil device may also promote positive remodeling of the ventricle to further decrease ventricle volume as the supported cardiac muscle more effectively contracts and expands, thus decreasing LVESVI by at least 5%.
- LVEF Left ventricle ejection fraction
- Implantation of the partitioning device increases the LVEF by at least about 5% and up to about 90%.
- indices of ventricular function may also be used for diagnosis and for therapeutic follow-up.
- a number of biochemical markers may be measured and used.
- One example is NT Pro-Brain Natriuretic Peptide, but many other biological molecules, for example, neurohormones, proteases, and proteins related to distressed or abnormal function may be measured to give quantification of the relative functionality of the ventricle prior and post-implant.
- NT-Pro-Brain Natriuretic Peptide is a regulatory peptide that is produced in the ventricle and has been shown to be related to the level of stress in myocardium, as well as involved in adverse remodeling processes seen in late stage disease.
- a normal NT-BNP level for a healthy individual is generally in the range of 20- 30 pg/ml, while in an individual with end stage heart failure, a level can be as high as 2000-3000 pg/ml, and in some instances there may be a correlation between BNP levels and LVEF.
- the use of NT-Pro-BNP levels as reliable markers for heart disease in a number of patient populations has been proposed (J.L. Januzzi; Cleve. Clin. J.
- the present invention contemplates treating a patient by first determining the level of NT-Pro-BNP, and if the level of NT-Pro-BNP is greater than 170pg/ml (third quartile) or 450pg/ml (fourth quaitile), delivering to such patient one or more of the devices herein. Implantation of a diastolic recoil device improves cardiac function, and decreases the level of NT-Pro-BNP observed post-implant by at least about 10%.
- Mitral valve regurgitation can be observed in patients with diastolic dysfunction, and is coupled to poor outcome. Mitral valve regurgitation increases in magnitude as the ventricle increases in size due to pathological dilation. Intervention is often necessary as blood backflow into the atrium leads to accelerated progression of heart failure. Standard therapies include both prescribed medications (i.e. vasodilators like ACE inhibitors and nitrates, and diuretics) and surgical interventions to repair or replace mitral valves. However, these surgical interventions are invasive and may present high risk to the patient. Diastolic recoil device implantation can reverse the decline in ventricular function by decreasing the effective ventricular volume which may obliterate or attenuate the cause of the mitral valve regurgitation.
- prescribed medications i.e. vasodilators like ACE inhibitors and nitrates, and diuretics
- surgical interventions are invasive and may present high risk to the patient. Diastolic recoil device implantation can reverse the decline in ventricular function by decreasing the effective ventricular volume
- the severity of mitral valve regurgitation is categorized by measuring the regurgitant fraction by, for example, echocardiography.
- Color Doppler flow on a transthoracic echocardiogram measures the forward flow through the mitral valve during ventricular diastole and compares it to the outflow of blood through the aortic valve in ventricular systole, permitting the calculation of die regurgitant fraction.
- the present invention contemplates treating a patient by first determining the degree of mitral regurgitation as assessed by the regurgitant fraction and if the regurgitant fraction is at least 20%, delivering to such patient one or more of the devices herein. Diastolic recoil device implantation may therefore benefit patients with mitral valve regurgitation from any clinically relevant cause and decrease the regurgitant fraction by at least about 10%.
- diastolic recoil device which is implanted in the left ventricle, it is understood by those skilled in the art that such reference is not limiting and similarly suitable diastolic recoil devices may be used in the right ventricle or other heart chambers.
- Classification levels II and III) diagnosed with ischemic cardiomyopathy post anterior infarction and systolic dysfunction were enrolled in a study implanting a diastolic recoil device similar to the one shown in Figure 1. Size selection of the specific device was based on echocardiography comparison with a mean landing zone diameter of 55.1mm (mean diastolic value or largest value achieved during cardiac cycle). Either 75mm (3/9 patients) or 85mm (6/9 patients) diameter devices were installed in a 95.7 minute (mean value) procedure, requiring mean fluoroscope time of 25.5 minutes. [00114] A number of hemodynamic and biochemical variables were examined in each patient before implant and at 90 day post implant and are represented in Table 1 below. Data is available for 4 patients at the 90 day timepoint.
- Left ventricle end systolic volume index (LVESVI) in a healthy individual is usually around 25ml/m 2 .
- the mean baseline value for the patient group is notably higher, at 101.8ml/m 2 .
- Significant reduction to 72.7ml/m 2 ( ⁇ 25%) for the LVESVI is observed at 90 days post implant.
- the ventricle has thus improved in function and was positively remodeled.
- LVEF Left ventricle ejection fraction
- NT-Pro-brain Natriuretic peptide (NT-Pro-BNP) levels for a healthy individual are estimated to be in the range of 20-30pg/ml.
- the baseline mean value of NT-Pro-BNP prior to implantation was 566pg/ml. This was significantly decreased by the 90 day timepoint to 363pg/ml, an improvement of about 36%.
- Table 2 represents data of overall functionality for the individual patients.
- the 6 minute walk is a simple test which measures the distance a patient is able to traverse during a 6 minutes timed period.
- the mean distance the patient cohort traveled prior to implant was 328m.
- Ninety days post implant, data available for 4 patients shows significant improvement (-44%) to 471m.
- the New York Heart Association (NYHA) Classification levels for the patients prior to implantation were Class II/I1I for this group. At the 90 day timepoint. reassessment of the NYHA Classification was performed on the four patients with available data. Three of the four individuals could be reassigned to less severe disease classifications.
- NYHA New York Heart Association
Abstract
Description
Claims
Priority Applications (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
AU2007333895A AU2007333895A1 (en) | 2006-12-14 | 2007-12-13 | Cardiac device and methods of use thereof |
CA002671974A CA2671974A1 (en) | 2006-12-14 | 2007-12-13 | Cardiac device and methods of use thereof |
JP2009541604A JP5461192B2 (en) | 2006-12-14 | 2007-12-13 | Heart disease device |
EP07865668A EP2091588A4 (en) | 2006-12-14 | 2007-12-13 | Cardiac device and methods of use thereof |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US11/640,469 US7674222B2 (en) | 1999-08-09 | 2006-12-14 | Cardiac device and methods of use thereof |
US11/640,469 | 2006-12-14 |
Publications (2)
Publication Number | Publication Date |
---|---|
WO2008076853A2 true WO2008076853A2 (en) | 2008-06-26 |
WO2008076853A3 WO2008076853A3 (en) | 2008-10-02 |
Family
ID=39537001
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/US2007/087497 WO2008076853A2 (en) | 2006-12-14 | 2007-12-13 | Cardiac device and methods of use thereof |
Country Status (6)
Country | Link |
---|---|
US (2) | US7674222B2 (en) |
EP (1) | EP2091588A4 (en) |
JP (1) | JP5461192B2 (en) |
AU (1) | AU2007333895A1 (en) |
CA (1) | CA2671974A1 (en) |
WO (1) | WO2008076853A2 (en) |
Cited By (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2012505699A (en) * | 2008-10-20 | 2012-03-08 | コーアシスト・カーデイオバスキユラー・リミテツド | Ventricular assist device and method and apparatus for implanting it |
US10967188B2 (en) | 2012-12-21 | 2021-04-06 | Backbeat Medical, Llc | Methods and systems for controlling blood pressure by controlling atrial pressure |
US11083894B2 (en) | 2008-09-08 | 2021-08-10 | Backbeat Medical, Llc | Methods and apparatus to stimulate the heart |
US11389658B2 (en) | 2015-09-11 | 2022-07-19 | Backbeat Medical, Llc | Methods and systems for treating cardiac malfunction |
US11406829B2 (en) | 2004-02-12 | 2022-08-09 | Backbeat Medical, Llc | Cardiac stimulation apparatus and method for the control of hypertension |
US11426589B2 (en) | 2016-04-22 | 2022-08-30 | Backbeat Medical, Llc | Methods and systems for controlling blood pressure |
US11529520B2 (en) | 2006-09-25 | 2022-12-20 | Backbeat Medical, Llc | Methods and apparatus to stimulate heart atria |
US11577059B2 (en) | 2005-03-02 | 2023-02-14 | Backbeat Medical, Llc | Methods and apparatus to increase secretion of endogenous naturetic hormones |
Families Citing this family (138)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US7883539B2 (en) | 1997-01-02 | 2011-02-08 | Edwards Lifesciences Llc | Heart wall tension reduction apparatus and method |
US7128073B1 (en) | 1998-11-06 | 2006-10-31 | Ev3 Endovascular, Inc. | Method and device for left atrial appendage occlusion |
US10307147B2 (en) | 1999-08-09 | 2019-06-04 | Edwards Lifesciences Corporation | System for improving cardiac function by sealing a partitioning membrane within a ventricle |
US8529430B2 (en) | 2002-08-01 | 2013-09-10 | Cardiokinetix, Inc. | Therapeutic methods and devices following myocardial infarction |
US7674222B2 (en) * | 1999-08-09 | 2010-03-09 | Cardiokinetix, Inc. | Cardiac device and methods of use thereof |
US8500795B2 (en) | 1999-08-09 | 2013-08-06 | Cardiokinetix, Inc. | Retrievable devices for improving cardiac function |
US8257428B2 (en) * | 1999-08-09 | 2012-09-04 | Cardiokinetix, Inc. | System for improving cardiac function |
US9694121B2 (en) | 1999-08-09 | 2017-07-04 | Cardiokinetix, Inc. | Systems and methods for improving cardiac function |
US8388672B2 (en) | 1999-08-09 | 2013-03-05 | Cardiokinetix, Inc. | System for improving cardiac function by sealing a partitioning membrane within a ventricle |
US9332993B2 (en) | 2004-08-05 | 2016-05-10 | Cardiokinetix, Inc. | Devices and methods for delivering an endocardial device |
US9332992B2 (en) | 2004-08-05 | 2016-05-10 | Cardiokinetix, Inc. | Method for making a laminar ventricular partitioning device |
US9078660B2 (en) * | 2000-08-09 | 2015-07-14 | Cardiokinetix, Inc. | Devices and methods for delivering an endocardial device |
US10064696B2 (en) | 2000-08-09 | 2018-09-04 | Edwards Lifesciences Corporation | Devices and methods for delivering an endocardial device |
US20060030881A1 (en) | 2004-08-05 | 2006-02-09 | Cardiokinetix, Inc. | Ventricular partitioning device |
US8398537B2 (en) | 2005-06-10 | 2013-03-19 | Cardiokinetix, Inc. | Peripheral seal for a ventricular partitioning device |
US7399271B2 (en) * | 2004-01-09 | 2008-07-15 | Cardiokinetix, Inc. | Ventricular partitioning device |
US7762943B2 (en) * | 2004-03-03 | 2010-07-27 | Cardiokinetix, Inc. | Inflatable ventricular partitioning device |
US6723038B1 (en) | 2000-10-06 | 2004-04-20 | Myocor, Inc. | Methods and devices for improving mitral valve function |
US6764510B2 (en) | 2002-01-09 | 2004-07-20 | Myocor, Inc. | Devices and methods for heart valve treatment |
US7112219B2 (en) | 2002-11-12 | 2006-09-26 | Myocor, Inc. | Devices and methods for heart valve treatment |
US11511102B2 (en) | 2004-06-17 | 2022-11-29 | The Texas A&M University System | Cardiac compression device having passive and active chambers |
US9510746B2 (en) | 2004-06-17 | 2016-12-06 | The Texas A&M University System | Deployment methods and mechanisms for minimally invasive implantation of heart contacting cardiac devices |
US20060079736A1 (en) | 2004-10-13 | 2006-04-13 | Sing-Fatt Chin | Method and device for percutaneous left ventricular reconstruction |
US7766816B2 (en) | 2005-06-09 | 2010-08-03 | Chf Technologies, Inc. | Method and apparatus for closing off a portion of a heart ventricle |
US20090082619A1 (en) * | 2005-06-09 | 2009-03-26 | De Marchena Eduardo | Method of treating cardiomyopathy |
WO2007022519A2 (en) | 2005-08-19 | 2007-02-22 | Chf Technologies, Inc. | Steerable heart implants for congestive heart failure |
US8506474B2 (en) | 2005-08-19 | 2013-08-13 | Bioventrix, Inc. | Method and device for treating dysfunctional cardiac tissue |
US7972359B2 (en) | 2005-09-16 | 2011-07-05 | Atritech, Inc. | Intracardiac cage and method of delivering same |
EP1986735A4 (en) * | 2006-02-06 | 2011-06-29 | Northwind Ventures | Systems and methods for volume reduction |
US7749249B2 (en) | 2006-02-21 | 2010-07-06 | Kardium Inc. | Method and device for closing holes in tissue |
US20070270688A1 (en) | 2006-05-19 | 2007-11-22 | Daniel Gelbart | Automatic atherectomy system |
US8920411B2 (en) | 2006-06-28 | 2014-12-30 | Kardium Inc. | Apparatus and method for intra-cardiac mapping and ablation |
US9119633B2 (en) | 2006-06-28 | 2015-09-01 | Kardium Inc. | Apparatus and method for intra-cardiac mapping and ablation |
US11389232B2 (en) | 2006-06-28 | 2022-07-19 | Kardium Inc. | Apparatus and method for intra-cardiac mapping and ablation |
US10028783B2 (en) | 2006-06-28 | 2018-07-24 | Kardium Inc. | Apparatus and method for intra-cardiac mapping and ablation |
US8449605B2 (en) | 2006-06-28 | 2013-05-28 | Kardium Inc. | Method for anchoring a mitral valve |
US7837610B2 (en) | 2006-08-02 | 2010-11-23 | Kardium Inc. | System for improving diastolic dysfunction |
US8123668B2 (en) | 2006-09-28 | 2012-02-28 | Bioventrix (A Chf Technologies' Company) | Signal transmitting and lesion excluding heart implants for pacing defibrillating and/or sensing of heart beat |
US9211115B2 (en) | 2006-09-28 | 2015-12-15 | Bioventrix, Inc. | Location, time, and/or pressure determining devices, systems, and methods for deployment of lesion-excluding heart implants for treatment of cardiac heart failure and other disease states |
US8029556B2 (en) | 2006-10-04 | 2011-10-04 | Edwards Lifesciences Corporation | Method and apparatus for reshaping a ventricle |
US9192471B2 (en) | 2007-01-08 | 2015-11-24 | Millipede, Inc. | Device for translumenal reshaping of a mitral valve annulus |
AU2008276523B2 (en) * | 2007-07-18 | 2014-08-21 | Boston Scientific Scimed, Inc. | Endoscopic implant system and method |
DE102007043830A1 (en) | 2007-09-13 | 2009-04-02 | Lozonschi, Lucian, Madison | Heart valve stent |
WO2009046343A1 (en) | 2007-10-03 | 2009-04-09 | Bioventrix (A Chf Technologies, Inc.) | Treating dysfunctional cardiac tissue |
US8906011B2 (en) | 2007-11-16 | 2014-12-09 | Kardium Inc. | Medical device for use in bodily lumens, for example an atrium |
EP2082690B1 (en) | 2008-01-24 | 2012-06-20 | Kardium, Inc. | Medical device to assist diastolic function and prevent ventricular enlargement |
US8489172B2 (en) | 2008-01-25 | 2013-07-16 | Kardium Inc. | Liposuction system |
US20090287304A1 (en) | 2008-05-13 | 2009-11-19 | Kardium Inc. | Medical Device for Constricting Tissue or a Bodily Orifice, for example a mitral valve |
WO2010042018A1 (en) * | 2008-10-10 | 2010-04-15 | Milux Holding S.A. | Heart help device, system and method |
AU2009302939B2 (en) * | 2008-10-10 | 2016-03-03 | Medicaltree Patent Ltd | Heart help device, system, and method |
US20100210899A1 (en) * | 2009-01-21 | 2010-08-19 | Tendyne Medical, Inc. | Method for percutaneous lateral access to the left ventricle for treatment of mitral insufficiency by papillary muscle alignment |
WO2010090878A2 (en) * | 2009-01-21 | 2010-08-12 | Tendyne Medical, Inc. | Apical papillary muscle attachment for left ventricular reduction |
US20100274227A1 (en) * | 2009-02-13 | 2010-10-28 | Alexander Khairkhahan | Delivery catheter handle cover |
US20110015476A1 (en) * | 2009-03-04 | 2011-01-20 | Jeff Franco | Devices and Methods for Treating Cardiomyopathy |
US9642957B2 (en) | 2009-07-22 | 2017-05-09 | The Texas A&M University System | Diastolic recoil method and device for treatment of cardiac pathologies |
JP5654013B2 (en) * | 2009-07-22 | 2015-01-14 | ザ テキサス エー アンド エム ユニヴァーシティー システムThe Texas A&M University System | Diastolic recoil method and device for treating a cardiac condition |
EP2482749B1 (en) | 2009-10-01 | 2017-08-30 | Kardium Inc. | Kit for constricting tissue or a bodily orifice, for example, a mitral valve |
AU2010315535A1 (en) | 2009-10-26 | 2012-05-03 | Cardiokinetix, Inc. | Ventricular volume reduction |
EP3300695B1 (en) | 2009-12-08 | 2023-05-24 | Avalon Medical Ltd. | Device and system for transcatheter mitral valve replacement |
US9050066B2 (en) | 2010-06-07 | 2015-06-09 | Kardium Inc. | Closing openings in anatomical tissue |
IT1400503B1 (en) * | 2010-06-08 | 2013-06-11 | Parravicini | CARDIOVASCULAR DEVICE. |
US20120053680A1 (en) | 2010-08-24 | 2012-03-01 | Bolling Steven F | Reconfiguring Heart Features |
US8940002B2 (en) | 2010-09-30 | 2015-01-27 | Kardium Inc. | Tissue anchor system |
CA2764494A1 (en) | 2011-01-21 | 2012-07-21 | Kardium Inc. | Enhanced medical device for use in bodily cavities, for example an atrium |
US9452016B2 (en) | 2011-01-21 | 2016-09-27 | Kardium Inc. | Catheter system |
US11259867B2 (en) | 2011-01-21 | 2022-03-01 | Kardium Inc. | High-density electrode-based medical device system |
US9486273B2 (en) | 2011-01-21 | 2016-11-08 | Kardium Inc. | High-density electrode-based medical device system |
US9072511B2 (en) | 2011-03-25 | 2015-07-07 | Kardium Inc. | Medical kit for constricting tissue or a bodily orifice, for example, a mitral valve |
WO2013028387A2 (en) | 2011-08-11 | 2013-02-28 | Tendyne Holdings, Inc. | Improvements for prosthetic valves and related inventions |
BR112014007686A2 (en) | 2011-09-30 | 2017-04-18 | Bioventrix Inc | method and system for heart treatment within the patient |
US10219931B2 (en) * | 2011-11-09 | 2019-03-05 | Easynotes Ltd. | Obstruction device |
US9827092B2 (en) | 2011-12-16 | 2017-11-28 | Tendyne Holdings, Inc. | Tethers for prosthetic mitral valve |
USD777925S1 (en) | 2012-01-20 | 2017-01-31 | Kardium Inc. | Intra-cardiac procedure device |
USD777926S1 (en) | 2012-01-20 | 2017-01-31 | Kardium Inc. | Intra-cardiac procedure device |
US9198592B2 (en) | 2012-05-21 | 2015-12-01 | Kardium Inc. | Systems and methods for activating transducers |
US9017321B2 (en) | 2012-05-21 | 2015-04-28 | Kardium, Inc. | Systems and methods for activating transducers |
US10827977B2 (en) | 2012-05-21 | 2020-11-10 | Kardium Inc. | Systems and methods for activating transducers |
WO2014022124A1 (en) | 2012-07-28 | 2014-02-06 | Tendyne Holdings, Inc. | Improved multi-component designs for heart valve retrieval device, sealing structures and stent assembly |
US9675454B2 (en) | 2012-07-30 | 2017-06-13 | Tendyne Holdings, Inc. | Delivery systems and methods for transcatheter prosthetic valves |
US10543088B2 (en) | 2012-09-14 | 2020-01-28 | Boston Scientific Scimed, Inc. | Mitral valve inversion prostheses |
US10849755B2 (en) | 2012-09-14 | 2020-12-01 | Boston Scientific Scimed, Inc. | Mitral valve inversion prostheses |
US11224510B2 (en) | 2013-04-02 | 2022-01-18 | Tendyne Holdings, Inc. | Prosthetic heart valve and systems and methods for delivering the same |
US9486306B2 (en) | 2013-04-02 | 2016-11-08 | Tendyne Holdings, Inc. | Inflatable annular sealing device for prosthetic mitral valve |
US10463489B2 (en) | 2013-04-02 | 2019-11-05 | Tendyne Holdings, Inc. | Prosthetic heart valve and systems and methods for delivering the same |
US10478293B2 (en) | 2013-04-04 | 2019-11-19 | Tendyne Holdings, Inc. | Retrieval and repositioning system for prosthetic heart valve |
BR112015029211A2 (en) | 2013-05-24 | 2017-07-25 | Bioventrix Inc | cardiac tissue penetration devices, methods, and systems for treating congestive heart failure and other conditions |
US9610159B2 (en) | 2013-05-30 | 2017-04-04 | Tendyne Holdings, Inc. | Structural members for prosthetic mitral valves |
US9592399B2 (en) | 2013-06-20 | 2017-03-14 | Cardiac Pacemakers, Inc. | Deployable multi-electrode leadless electrostimulator |
CN108814772B (en) | 2013-06-25 | 2020-09-08 | 坦迪尼控股股份有限公司 | Thrombus management and structural compliance features for prosthetic heart valves |
CA2919379C (en) | 2013-08-01 | 2021-03-30 | Tendyne Holdings, Inc. | Epicardial anchor devices and methods |
WO2015031839A1 (en) | 2013-08-30 | 2015-03-05 | Bioventrix, Inc. | Heart anchor positioning devices, methods, and systems for treatment of congestive heart failure and other conditions |
US10588613B2 (en) | 2013-08-30 | 2020-03-17 | Bioventrix, Inc. | Cardiac tissue anchoring devices, methods, and systems for treatment of congestive heart failure and other conditions |
WO2015058039A1 (en) | 2013-10-17 | 2015-04-23 | Robert Vidlund | Apparatus and methods for alignment and deployment of intracardiac devices |
CN105682611B (en) | 2013-10-28 | 2018-06-01 | 坦迪尼控股股份有限公司 | Prosthetic heart valve and the system and method for conveying prosthetic heart valve |
US9526611B2 (en) | 2013-10-29 | 2016-12-27 | Tendyne Holdings, Inc. | Apparatus and methods for delivery of transcatheter prosthetic valves |
WO2015120122A2 (en) | 2014-02-05 | 2015-08-13 | Robert Vidlund | Apparatus and methods for transfemoral delivery of prosthetic mitral valve |
US9986993B2 (en) | 2014-02-11 | 2018-06-05 | Tendyne Holdings, Inc. | Adjustable tether and epicardial pad system for prosthetic heart valve |
CN103800045A (en) * | 2014-02-24 | 2014-05-21 | 梅奇峰 | Medical cardiac tamponade object |
CA2937566C (en) | 2014-03-10 | 2023-09-05 | Tendyne Holdings, Inc. | Devices and methods for positioning and monitoring tether load for prosthetic mitral valve |
US9974647B2 (en) * | 2014-06-12 | 2018-05-22 | Caisson Interventional, LLC | Two stage anchor and mitral valve assembly |
US9180005B1 (en) | 2014-07-17 | 2015-11-10 | Millipede, Inc. | Adjustable endolumenal mitral valve ring |
CN106852115A (en) | 2014-09-28 | 2017-06-13 | 卡迪欧凯尼迪克斯公司 | device for treating cardiac insufficiency |
US10722184B2 (en) | 2014-11-17 | 2020-07-28 | Kardium Inc. | Systems and methods for selecting, activating, or selecting and activating transducers |
US10368936B2 (en) | 2014-11-17 | 2019-08-06 | Kardium Inc. | Systems and methods for selecting, activating, or selecting and activating transducers |
JP6826035B2 (en) | 2015-01-07 | 2021-02-03 | テンダイン ホールディングス,インコーポレイテッド | Artificial mitral valve, and devices and methods for its delivery |
CA2975294A1 (en) | 2015-02-05 | 2016-08-11 | Tendyne Holdings, Inc. | Expandable epicardial pads and devices and methods for delivery of same |
CN107530166B (en) | 2015-02-13 | 2020-01-31 | 魅尔皮德股份有限公司 | Valve replacement using a rotating anchor |
WO2016168609A1 (en) | 2015-04-16 | 2016-10-20 | Tendyne Holdings, Inc. | Apparatus and methods for delivery, repositioning, and retrieval of transcatheter prosthetic valves |
US9833551B2 (en) | 2015-04-29 | 2017-12-05 | The Texas A&M University System | Fully implantable direct cardiac and aortic compression device |
JP6630427B2 (en) | 2015-07-15 | 2020-01-15 | ザ テキサス エー アンド エム ユニヴァーシティー システムThe Texas A&M University System | Self-expanding assisted heart |
US10206779B2 (en) | 2015-09-10 | 2019-02-19 | Bioventrix, Inc. | Systems and methods for deploying a cardiac anchor |
US10327894B2 (en) | 2015-09-18 | 2019-06-25 | Tendyne Holdings, Inc. | Methods for delivery of prosthetic mitral valves |
US10335275B2 (en) | 2015-09-29 | 2019-07-02 | Millipede, Inc. | Methods for delivery of heart valve devices using intravascular ultrasound imaging |
US10555813B2 (en) | 2015-11-17 | 2020-02-11 | Boston Scientific Scimed, Inc. | Implantable device and delivery system for reshaping a heart valve annulus |
CN108430391B (en) | 2015-12-03 | 2020-09-08 | 坦迪尼控股股份有限公司 | Frame features for prosthetic mitral valves |
CA3006010C (en) | 2015-12-28 | 2023-09-26 | Tendyne Holdings, Inc. | Atrial pocket closures for prosthetic heart valves |
CA3009429A1 (en) * | 2015-12-29 | 2017-07-06 | Shenzhen Kyd Biomedical Technology Co.Ltd | Left atrial appendage closure apparatus |
EP3397208B1 (en) | 2015-12-30 | 2020-12-02 | Caisson Interventional, LLC | Systems for heart valve therapy |
US11478353B2 (en) | 2016-01-29 | 2022-10-25 | Bioventrix, Inc. | Percutaneous arterial access to position trans-myocardial implant devices and methods |
WO2017189276A1 (en) * | 2016-04-29 | 2017-11-02 | Medtronic Vascular Inc. | Prosthetic heart valve devices with tethered anchors and associated systems and methods |
US10470877B2 (en) | 2016-05-03 | 2019-11-12 | Tendyne Holdings, Inc. | Apparatus and methods for anterior valve leaflet management |
WO2017218375A1 (en) | 2016-06-13 | 2017-12-21 | Tendyne Holdings, Inc. | Sequential delivery of two-part prosthetic mitral valve |
US10507271B2 (en) | 2016-06-23 | 2019-12-17 | Corinnova Incorporated | Fully implantable direct myocardium assist device |
WO2018005779A1 (en) | 2016-06-30 | 2018-01-04 | Tegels Zachary J | Prosthetic heart valves and apparatus and methods for delivery of same |
EP3484411A1 (en) | 2016-07-12 | 2019-05-22 | Tendyne Holdings, Inc. | Apparatus and methods for trans-septal retrieval of prosthetic heart valves |
JP6949973B2 (en) * | 2016-10-23 | 2021-10-13 | サニカチャラム モハン | Ventricular ejection device |
WO2018148584A1 (en) | 2017-02-10 | 2018-08-16 | Millipede, Inc. | Implantable device and delivery system for reshaping a heart valve annulus |
US10898330B2 (en) | 2017-03-28 | 2021-01-26 | Edwards Lifesciences Corporation | Positioning, deploying, and retrieving implantable devices |
CN208958226U (en) * | 2017-05-23 | 2019-06-11 | 杭州诺茂医疗科技有限公司 | A kind of occluder for left auricle of closed loop configuration |
EP3651695B1 (en) | 2017-07-13 | 2023-04-19 | Tendyne Holdings, Inc. | Prosthetic heart valves and apparatus for delivery of same |
CN111031967B (en) | 2017-08-28 | 2022-08-09 | 坦迪尼控股股份有限公司 | Prosthetic heart valve with tether connection features |
US11648110B2 (en) | 2019-12-05 | 2023-05-16 | Tendyne Holdings, Inc. | Braided anchor for mitral valve |
US11648114B2 (en) | 2019-12-20 | 2023-05-16 | Tendyne Holdings, Inc. | Distally loaded sheath and loading funnel |
IT202000001252A1 (en) | 2020-01-23 | 2021-07-23 | Eucardia S R L | CARDIOVASCULAR DEVICE AND KIT FOR THE REDUCTION OF A HEART CAVITY |
US11951002B2 (en) | 2020-03-30 | 2024-04-09 | Tendyne Holdings, Inc. | Apparatus and methods for valve and tether fixation |
CN111643145B (en) * | 2020-06-28 | 2021-07-20 | 哈尔滨工业大学 | Left auricle occluder and preparation method thereof |
WO2022039853A1 (en) | 2020-08-19 | 2022-02-24 | Tendyne Holdings, Inc. | Fully-transseptal apical pad with pulley for tensioning |
CN114617676A (en) * | 2022-02-15 | 2022-06-14 | 源深(深圳)医疗器械有限责任公司 | Elastic spring type ventricular diastole auxiliary device and personalized customization method thereof |
Family Cites Families (208)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3874388A (en) | 1973-02-12 | 1975-04-01 | Ochsner Med Found Alton | Shunt defect closure system |
US4007743A (en) | 1975-10-20 | 1977-02-15 | American Hospital Supply Corporation | Opening mechanism for umbrella-like intravascular shunt defect closure device |
FR2470593A2 (en) | 1979-01-22 | 1981-06-12 | Lapeyre Didier | NEW TOTAL HEART PROSTHESIS |
JPS6010740B2 (en) | 1981-05-07 | 1985-03-19 | 宏司 井上 | Endotracheal tube for unilateral lung ventilation |
US4425908A (en) | 1981-10-22 | 1984-01-17 | Beth Israel Hospital | Blood clot filter |
IT1155105B (en) | 1982-03-03 | 1987-01-21 | Roberto Parravicini | PLANT DEVICE TO SUPPORT THE MYOCARDIUM ACTIVITY |
US5104399A (en) | 1986-12-10 | 1992-04-14 | Endovascular Technologies, Inc. | Artificial graft and implantation method |
US4685446A (en) | 1984-02-21 | 1987-08-11 | Choy Daniel S J | Method for using a ventricular assist device |
DK151404C (en) | 1984-05-23 | 1988-07-18 | Cook Europ Aps William | FULLY FILTER FOR IMPLANTATION IN A PATIENT'S BLOOD |
US4710192A (en) | 1985-12-30 | 1987-12-01 | Liotta Domingo S | Diaphragm and method for occlusion of the descending thoracic aorta |
US5527337A (en) | 1987-06-25 | 1996-06-18 | Duke University | Bioabsorbable stent and method of making the same |
US4819751A (en) | 1987-10-16 | 1989-04-11 | Baxter Travenol Laboratories, Inc. | Valvuloplasty catheter and method |
US4832055A (en) | 1988-07-08 | 1989-05-23 | Palestrant Aubrey M | Mechanically locking blood clot filter |
US4917089A (en) | 1988-08-29 | 1990-04-17 | Sideris Eleftherios B | Buttoned device for the transvenous occlusion of intracardiac defects |
FR2641692A1 (en) | 1989-01-17 | 1990-07-20 | Nippon Zeon Co | Plug for closing an opening for a medical application, and device for the closure plug making use thereof |
US4983165A (en) | 1990-01-23 | 1991-01-08 | Loiterman David A | Guidance system for vascular catheter or the like |
US5221261A (en) | 1990-04-12 | 1993-06-22 | Schneider (Usa) Inc. | Radially expandable fixation member |
US5389087A (en) | 1991-09-19 | 1995-02-14 | Baxter International Inc. | Fully exchangeable over-the-wire catheter with rip seam and gated side port |
CA2082090C (en) | 1991-11-05 | 2004-04-27 | Jack Fagan | Improved occluder for repair of cardiac and vascular defects |
EP0545091B1 (en) | 1991-11-05 | 1999-07-07 | The Children's Medical Center Corporation | Occluder for repair of cardiac and vascular defects |
US5192314A (en) | 1991-12-12 | 1993-03-09 | Daskalakis Michael K | Synthetic intraventricular implants and method of inserting |
US5683366A (en) | 1992-01-07 | 1997-11-04 | Arthrocare Corporation | System and method for electrosurgical tissue canalization |
FR2689388B1 (en) | 1992-04-07 | 1999-07-16 | Celsa Lg | PERFECTIONALLY RESORBABLE BLOOD FILTER. |
US5707362A (en) | 1992-04-15 | 1998-01-13 | Yoon; Inbae | Penetrating instrument having an expandable anchoring portion for triggering protrusion of a safety member and/or retraction of a penetrating member |
US5766246A (en) | 1992-05-20 | 1998-06-16 | C. R. Bard, Inc. | Implantable prosthesis and method and apparatus for loading and delivering an implantable prothesis |
US5527338A (en) | 1992-09-02 | 1996-06-18 | Board Of Regents, The University Of Texas System | Intravascular device |
US6125852A (en) | 1993-02-22 | 2000-10-03 | Heartport, Inc. | Minimally-invasive devices and methods for treatment of congestive heart failure |
US6161543A (en) | 1993-02-22 | 2000-12-19 | Epicor, Inc. | Methods of epicardial ablation for creating a lesion around the pulmonary veins |
US5797960A (en) | 1993-02-22 | 1998-08-25 | Stevens; John H. | Method and apparatus for thoracoscopic intracardiac procedures |
ATE194469T1 (en) | 1993-03-16 | 2000-07-15 | Ep Technologies | CARRIER ARRANGEMENT FOR MULTIPLE ELECTRODES |
US5549621A (en) | 1993-05-14 | 1996-08-27 | Byron C. Sutherland | Apparatus and method for performing vertical banded gastroplasty |
US5791231A (en) | 1993-05-17 | 1998-08-11 | Endorobotics Corporation | Surgical robotic system and hydraulic actuator therefor |
US6258021B1 (en) | 1993-06-17 | 2001-07-10 | Peter J. Wilk | Intrapericardial assist method |
US6776754B1 (en) | 2000-10-04 | 2004-08-17 | Wilk Patent Development Corporation | Method for closing off lower portion of heart ventricle |
US6155968A (en) * | 1998-07-23 | 2000-12-05 | Wilk; Peter J. | Method and device for improving cardiac function |
US5385156A (en) | 1993-08-27 | 1995-01-31 | Rose Health Care Systems | Diagnostic and treatment method for cardiac rupture and apparatus for performing the same |
US5876325A (en) | 1993-11-02 | 1999-03-02 | Olympus Optical Co., Ltd. | Surgical manipulation system |
US5634942A (en) | 1994-04-21 | 1997-06-03 | B. Braun Celsa | Assembly comprising a blood filter for temporary or definitive use and a device for implanting it |
ES2340142T3 (en) | 1994-07-08 | 2010-05-31 | Ev3 Inc. | SYSTEM TO CARRY OUT AN INTRAVASCULAR PROCEDURE. |
US5582616A (en) | 1994-08-05 | 1996-12-10 | Origin Medsystems, Inc. | Surgical helical fastener with applicator |
US5433727A (en) | 1994-08-16 | 1995-07-18 | Sideris; Eleftherios B. | Centering buttoned device for the occlusion of large defects for occluding |
US5843170A (en) | 1994-09-02 | 1998-12-01 | Ahn; Sam Seunghae | Apparatus and method for performing aneurysm repair |
US5879366A (en) | 1996-12-20 | 1999-03-09 | W.L. Gore & Associates, Inc. | Self-expanding defect closure device and method of making and using |
US5634936A (en) | 1995-02-06 | 1997-06-03 | Scimed Life Systems, Inc. | Device for closing a septal defect |
JPH08257031A (en) | 1995-03-24 | 1996-10-08 | Toshio Saeki | Filter |
US5797849A (en) | 1995-03-28 | 1998-08-25 | Sonometrics Corporation | Method for carrying out a medical procedure using a three-dimensional tracking and imaging system |
ATE169484T1 (en) | 1995-04-01 | 1998-08-15 | Variomed Ag | STENT FOR TRANSLUMINAL IMPLANTATION IN HOLLOW ORGANS |
WO1996036297A1 (en) | 1995-05-19 | 1996-11-21 | Kanji Inoue | Transplantation instrument, method of bending same and method of transplanting same |
US5551435A (en) | 1995-05-26 | 1996-09-03 | Sramek; Bohumir | Method and system for managing hemodynamic state and oxygen transport |
US5758664A (en) | 1995-06-07 | 1998-06-02 | W. L. Gore & Associates, Inc. | Method of maintaining a left ventricular assist device |
US6132438A (en) | 1995-06-07 | 2000-10-17 | Ep Technologies, Inc. | Devices for installing stasis reducing means in body tissue |
US5800528A (en) | 1995-06-13 | 1998-09-01 | Abiomed R & D, Inc. | Passive girdle for heart ventricle for therapeutic aid to patients having ventricular dilatation |
DE69612507T2 (en) | 1995-10-30 | 2001-08-09 | Childrens Medical Center | SELF-CENTERING, SHIELD-LIKE DEVICE FOR CLOSING A SEPTAL DEFECT |
US5578069A (en) | 1995-12-06 | 1996-11-26 | Vnetritex, Inc. | Electrode deployment mechanism and method using artificial muscle |
US6168622B1 (en) | 1996-01-24 | 2001-01-02 | Microvena Corporation | Method and apparatus for occluding aneurysms |
DE19604817C2 (en) | 1996-02-09 | 2003-06-12 | Pfm Prod Fuer Die Med Ag | Device for closing defect openings in the human or animal body |
US5853422A (en) | 1996-03-22 | 1998-12-29 | Scimed Life Systems, Inc. | Apparatus and method for closing a septal defect |
US5669933A (en) | 1996-07-17 | 1997-09-23 | Nitinol Medical Technologies, Inc. | Removable embolus blood clot filter |
US5833698A (en) | 1996-07-23 | 1998-11-10 | United States Surgical Corporation | Anastomosis instrument and method |
US5826576A (en) | 1996-08-08 | 1998-10-27 | Medtronic, Inc. | Electrophysiology catheter with multifunction wire and method for making |
US5702343A (en) | 1996-10-02 | 1997-12-30 | Acorn Medical, Inc. | Cardiac reinforcement device |
WO1998016164A1 (en) | 1996-10-15 | 1998-04-23 | Mayer Paul W | Relative motion canceling platform for surgery |
US5861003A (en) | 1996-10-23 | 1999-01-19 | The Cleveland Clinic Foundation | Apparatus and method for occluding a defect or aperture within body surface |
CA2267449C (en) | 1996-11-05 | 2008-10-14 | Purdue Research Foundation | Myocardial graft constructs |
US5875782A (en) | 1996-11-14 | 1999-03-02 | Cardiothoracic Systems, Inc. | Methods and devices for minimally invasive coronary artery revascularization on a beating heart without cardiopulmonary bypass |
US5941893A (en) | 1996-12-02 | 1999-08-24 | Angiotrax, Inc. | Apparatus for transluminally performing surgery |
US6406420B1 (en) | 1997-01-02 | 2002-06-18 | Myocor, Inc. | Methods and devices for improving cardiac function in hearts |
US6077214A (en) | 1998-07-29 | 2000-06-20 | Myocor, Inc. | Stress reduction apparatus and method |
US6050936A (en) | 1997-01-02 | 2000-04-18 | Myocor, Inc. | Heart wall tension reduction apparatus |
US5961440A (en) | 1997-01-02 | 1999-10-05 | Myocor, Inc. | Heart wall tension reduction apparatus and method |
US6045497A (en) | 1997-01-02 | 2000-04-04 | Myocor, Inc. | Heart wall tension reduction apparatus and method |
US5961539A (en) | 1997-01-17 | 1999-10-05 | Segmed, Inc. | Method and apparatus for sizing, stabilizing and/or reducing the circumference of an anatomical structure |
US5800457A (en) | 1997-03-05 | 1998-09-01 | Gelbfish; Gary A. | Intravascular filter and associated methodology |
US6099832A (en) | 1997-05-28 | 2000-08-08 | Genzyme Corporation | Transplants for myocardial scars |
US5928260A (en) | 1997-07-10 | 1999-07-27 | Scimed Life Systems, Inc. | Removable occlusion system for aneurysm neck |
US6361545B1 (en) | 1997-09-26 | 2002-03-26 | Cardeon Corporation | Perfusion filter catheter |
US6190352B1 (en) | 1997-10-01 | 2001-02-20 | Boston Scientific Corporation | Guidewire compatible port and method for inserting same |
US5865730A (en) | 1997-10-07 | 1999-02-02 | Ethicon Endo-Surgery, Inc. | Tissue stabilization device for use during surgery having remotely actuated feet |
AU1170199A (en) | 1997-11-07 | 1999-05-31 | Ave Connaught | Balloon catheter for repairing bifurcated vessels |
US6036720A (en) | 1997-12-15 | 2000-03-14 | Target Therapeutics, Inc. | Sheet metal aneurysm neck bridge |
JP3799810B2 (en) | 1998-03-30 | 2006-07-19 | ニプロ株式会社 | Transcatheter surgery closure plug and catheter assembly |
US6095968A (en) | 1998-04-10 | 2000-08-01 | Cardio Technologies, Inc. | Reinforcement device |
US6450989B2 (en) | 1998-04-27 | 2002-09-17 | Artemis Medical, Inc. | Dilating and support apparatus with disease inhibitors and methods for use |
US6024096A (en) | 1998-05-01 | 2000-02-15 | Correstore Inc | Anterior segment ventricular restoration apparatus and method |
US6221104B1 (en) | 1998-05-01 | 2001-04-24 | Cor Restore, Inc. | Anterior and interior segment cardiac restoration apparatus and method |
US6544167B2 (en) | 1998-05-01 | 2003-04-08 | Correstore, Inc. | Ventricular restoration patch |
US7569062B1 (en) | 1998-07-15 | 2009-08-04 | St. Jude Medical, Inc. | Mitral and tricuspid valve repair |
US6547821B1 (en) | 1998-07-16 | 2003-04-15 | Cardiothoracic Systems, Inc. | Surgical procedures and devices for increasing cardiac output of the heart |
US6093199A (en) | 1998-08-05 | 2000-07-25 | Endovascular Technologies, Inc. | Intra-luminal device for treatment of body cavities and lumens and method of use |
US5916145A (en) | 1998-08-07 | 1999-06-29 | Scimed Life Systems, Inc. | Device and method of using a surgical assembly with mesh sheath |
US6102887A (en) | 1998-08-11 | 2000-08-15 | Biocardia, Inc. | Catheter drug delivery system and method for use |
WO2000012152A1 (en) | 1998-08-28 | 2000-03-09 | Juan Hernandez Herrero | Apparatus aiding physiologic systolic and diastolic dynamics of cardiac cavities |
US6342062B1 (en) | 1998-09-24 | 2002-01-29 | Scimed Life Systems, Inc. | Retrieval devices for vena cava filter |
US6360749B1 (en) | 1998-10-09 | 2002-03-26 | Swaminathan Jayaraman | Modification of properties and geometry of heart tissue to influence heart function |
US6685627B2 (en) | 1998-10-09 | 2004-02-03 | Swaminathan Jayaraman | Modification of properties and geometry of heart tissue to influence heart function |
US6193731B1 (en) | 1998-10-27 | 2001-02-27 | Fziomed, Inc. | Laparoscopic insertion and deployment device |
US7128073B1 (en) | 1998-11-06 | 2006-10-31 | Ev3 Endovascular, Inc. | Method and device for left atrial appendage occlusion |
US7044134B2 (en) | 1999-11-08 | 2006-05-16 | Ev3 Sunnyvale, Inc | Method of implanting a device in the left atrial appendage |
US7713282B2 (en) | 1998-11-06 | 2010-05-11 | Atritech, Inc. | Detachable atrial appendage occlusion balloon |
US6152144A (en) | 1998-11-06 | 2000-11-28 | Appriva Medical, Inc. | Method and device for left atrial appendage occlusion |
US6230714B1 (en) | 1998-11-18 | 2001-05-15 | Acorn Cardiovascular, Inc. | Cardiac constraint with prior venus occlusion methods |
US6083239A (en) | 1998-11-24 | 2000-07-04 | Embol-X, Inc. | Compliant framework and methods of use |
US6076013A (en) | 1999-01-14 | 2000-06-13 | Brennan; Edward F. | Apparatus and methods for treating congestive heart failure |
US6558418B2 (en) | 1999-01-26 | 2003-05-06 | Edwards Lifesciences Corporation | Flexible heart valve |
JP2003516111A (en) | 1999-02-22 | 2003-05-13 | バリアジェニックス インコーポレーテッド | Genetic sequence variants with utility in determining treatment for disease |
US6743196B2 (en) | 1999-03-01 | 2004-06-01 | Coaxia, Inc. | Partial aortic occlusion devices and methods for cerebral perfusion augmentation |
US6348068B1 (en) | 1999-07-23 | 2002-02-19 | Sulzer Carbomedics Inc. | Multi-filament valve stent for a cardisc valvular prosthesis |
US7303526B2 (en) | 1999-08-09 | 2007-12-04 | Cardiokinetix, Inc. | Device for improving cardiac function |
US8257428B2 (en) | 1999-08-09 | 2012-09-04 | Cardiokinetix, Inc. | System for improving cardiac function |
US7674222B2 (en) | 1999-08-09 | 2010-03-09 | Cardiokinetix, Inc. | Cardiac device and methods of use thereof |
US20030109770A1 (en) | 1999-08-09 | 2003-06-12 | Sharkey Hugh R. | Device with a porous membrane for improving cardiac function |
US7582051B2 (en) | 2005-06-10 | 2009-09-01 | Cardiokinetix, Inc. | Peripheral seal for a ventricular partitioning device |
US8529430B2 (en) | 2002-08-01 | 2013-09-10 | Cardiokinetix, Inc. | Therapeutic methods and devices following myocardial infarction |
US8500795B2 (en) | 1999-08-09 | 2013-08-06 | Cardiokinetix, Inc. | Retrievable devices for improving cardiac function |
US20060229491A1 (en) | 2002-08-01 | 2006-10-12 | Cardiokinetix, Inc. | Method for treating myocardial rupture |
US8388672B2 (en) | 1999-08-09 | 2013-03-05 | Cardiokinetix, Inc. | System for improving cardiac function by sealing a partitioning membrane within a ventricle |
US6231561B1 (en) | 1999-09-20 | 2001-05-15 | Appriva Medical, Inc. | Method and apparatus for closing a body lumen |
US6652555B1 (en) | 1999-10-27 | 2003-11-25 | Atritech, Inc. | Barrier device for covering the ostium of left atrial appendage |
US6689150B1 (en) | 1999-10-27 | 2004-02-10 | Atritech, Inc. | Filter apparatus for ostium of left atrial appendage |
US6551303B1 (en) | 1999-10-27 | 2003-04-22 | Atritech, Inc. | Barrier device for ostium of left atrial appendage |
US6994092B2 (en) | 1999-11-08 | 2006-02-07 | Ev3 Sunnyvale, Inc. | Device for containing embolic material in the LAA having a plurality of tissue retention structures |
US6645199B1 (en) | 1999-11-22 | 2003-11-11 | Scimed Life Systems, Inc. | Loop structures for supporting diagnostic and therapeutic elements contact with body tissue and expandable push devices for use with same |
WO2001067985A1 (en) | 2000-03-10 | 2001-09-20 | Paracor Surgical, Inc. | Expandable cardiac harness for treating congestive heart failure |
US6537198B1 (en) | 2000-03-21 | 2003-03-25 | Myocor, Inc. | Splint assembly for improving cardiac function in hearts, and method for implanting the splint assembly |
WO2001072309A2 (en) | 2000-03-28 | 2001-10-04 | Medicure International Inc. | Treatment of cerebrovascular disease |
US6334864B1 (en) | 2000-05-17 | 2002-01-01 | Aga Medical Corp. | Alignment member for delivering a non-symmetric device with a predefined orientation |
US6459917B1 (en) | 2000-05-22 | 2002-10-01 | Ashok Gowda | Apparatus for access to interstitial fluid, blood, or blood plasma components |
US6951534B2 (en) | 2000-06-13 | 2005-10-04 | Acorn Cardiovascular, Inc. | Cardiac support device |
US6482146B1 (en) | 2000-06-13 | 2002-11-19 | Acorn Cardiovascular, Inc. | Cardiac disease treatment and device |
US6572643B1 (en) | 2000-07-19 | 2003-06-03 | Vascular Architects, Inc. | Endoprosthesis delivery catheter assembly and method |
US6343605B1 (en) | 2000-08-08 | 2002-02-05 | Scimed Life Systems, Inc. | Percutaneous transluminal myocardial implantation device and method |
US7762943B2 (en) | 2004-03-03 | 2010-07-27 | Cardiokinetix, Inc. | Inflatable ventricular partitioning device |
US7399271B2 (en) | 2004-01-09 | 2008-07-15 | Cardiokinetix, Inc. | Ventricular partitioning device |
US8398537B2 (en) | 2005-06-10 | 2013-03-19 | Cardiokinetix, Inc. | Peripheral seal for a ventricular partitioning device |
US20060030881A1 (en) | 2004-08-05 | 2006-02-09 | Cardiokinetix, Inc. | Ventricular partitioning device |
US7862500B2 (en) | 2002-08-01 | 2011-01-04 | Cardiokinetix, Inc. | Multiple partitioning devices for heart treatment |
US6887192B1 (en) | 2000-09-08 | 2005-05-03 | Converge Medical, Inc. | Heart support to prevent ventricular remodeling |
US7510572B2 (en) | 2000-09-12 | 2009-03-31 | Shlomo Gabbay | Implantation system for delivery of a heart valve prosthesis |
US6511496B1 (en) | 2000-09-12 | 2003-01-28 | Advanced Cardiovascular Systems, Inc. | Embolic protection device for use in interventional procedures |
AU2002213231A1 (en) | 2000-10-18 | 2002-04-29 | Nmt Medical, Inc. | Over-the-wire interlock attachment/detachment mechanism |
US6482228B1 (en) | 2000-11-14 | 2002-11-19 | Troy R. Norred | Percutaneous aortic valve replacement |
MXPA03005130A (en) | 2000-12-07 | 2004-12-06 | Neuromolecular Inc | Methods for treating neuropsychiatric disorders with nmda receptor antagonists. |
US20040122090A1 (en) | 2001-12-07 | 2004-06-24 | Lipton Stuart A. | Methods for treating neuropsychiatric disorders with nmda receptor antagonists |
US20020133227A1 (en) | 2001-02-28 | 2002-09-19 | Gregory Murphy | Ventricular restoration patch apparatus and method of use |
US6702763B2 (en) | 2001-02-28 | 2004-03-09 | Chase Medical, L.P. | Sizing apparatus and method for use during ventricular restoration |
JP2005508201A (en) | 2001-03-08 | 2005-03-31 | アトリテック, インコーポレイテッド | Atrial filter implant |
US6622730B2 (en) | 2001-03-30 | 2003-09-23 | Myocor, Inc. | Device for marking and aligning positions on the heart |
US20050096498A1 (en) | 2001-04-24 | 2005-05-05 | Houser Russell A. | Sizing and shaping device for treating congestive heart failure |
US20020188170A1 (en) | 2001-04-27 | 2002-12-12 | Santamore William P. | Prevention of myocardial infarction induced ventricular expansion and remodeling |
IL158546A0 (en) | 2001-04-27 | 2004-05-12 | Myomend Inc | Prevention of myocardial infarction induced ventricular expansion and remodeling |
US7311731B2 (en) | 2001-04-27 | 2007-12-25 | Richard C. Satterfield | Prevention of myocardial infarction induced ventricular expansion and remodeling |
US20040064014A1 (en) | 2001-05-31 | 2004-04-01 | Melvin David B. | Devices and methods for assisting natural heart function |
CA2453658C (en) | 2001-07-16 | 2013-04-16 | Relaxis Ltd. | In-vivo method and device for improving diastolic function of the left ventricle |
US6592608B2 (en) | 2001-12-07 | 2003-07-15 | Biopsy Sciences, Llc | Bioabsorbable sealant |
US20060025800A1 (en) | 2001-09-05 | 2006-02-02 | Mitta Suresh | Method and device for surgical ventricular repair |
US7485088B2 (en) | 2001-09-05 | 2009-02-03 | Chase Medical L.P. | Method and device for percutaneous surgical ventricular repair |
US20060063970A1 (en) | 2002-09-06 | 2006-03-23 | Mardil, Inc. | Method and apparatus for external stabilization of the heart valves and myocardium |
US7144363B2 (en) * | 2001-10-16 | 2006-12-05 | Extensia Medical, Inc. | Systems for heart treatment |
US20050177180A1 (en) | 2001-11-28 | 2005-08-11 | Aptus Endosystems, Inc. | Devices, systems, and methods for supporting tissue and/or structures within a hollow body organ |
US7306574B2 (en) | 2002-01-17 | 2007-12-11 | Optivia Medical, Llc | Steerable dilatation system, dilator, and related methods for stepped dilatation |
CN1638703A (en) | 2002-01-25 | 2005-07-13 | 阿特里泰克公司 | Atrial appendage blood filtration systems |
US20050043708A1 (en) | 2002-01-31 | 2005-02-24 | Gleeson James B | Anastomosis device and method |
US7025759B2 (en) | 2002-02-04 | 2006-04-11 | Ebi, L.P. | Steerable catheter |
EP1482860B1 (en) | 2002-03-05 | 2007-11-14 | Salviac Limited | System with embolic filter and retracting snare |
AU2002304965A1 (en) | 2002-05-24 | 2003-12-12 | Zensun (Shanghai) Sci-Tech.Ltd | Neuregulin based methods and compositions for treating viral myocarditis and dilated cardiomyopathy |
EP1551334A4 (en) | 2002-06-10 | 2006-12-13 | Leo Rubin | Medical device for intra-lumenal delivery of pharmaceutical agents |
US20040136992A1 (en) | 2002-08-28 | 2004-07-15 | Burton Paul B. J. | Compositions and method for treating cardiovascular disease |
US6981984B2 (en) | 2002-09-17 | 2006-01-03 | Lee Don W | Stent with combined distal protection device |
AU2003277118A1 (en) | 2002-10-01 | 2004-04-23 | Ample Medical, Inc. | Devices for retaining native heart valve leaflet |
US20040133062A1 (en) | 2002-10-11 | 2004-07-08 | Suresh Pai | Minimally invasive cardiac force transfer structures |
AU2004208576B2 (en) | 2003-01-27 | 2009-08-20 | Corassist Cardiovascular Ltd. | In vivo device for improving diastolic ventricular function |
US20040260346A1 (en) | 2003-01-31 | 2004-12-23 | Overall William Ryan | Detection of apex motion for monitoring cardiac dysfunction |
US7294135B2 (en) | 2003-03-20 | 2007-11-13 | Medtronic Vascular, Inc | Control handle for intraluminal devices |
US7597704B2 (en) | 2003-04-28 | 2009-10-06 | Atritech, Inc. | Left atrial appendage occlusion device with active expansion |
US20040260331A1 (en) | 2003-06-20 | 2004-12-23 | D'aquanni Peter | Beta titanium embolic protection frame and guide wire |
BR0302240B8 (en) | 2003-06-24 | 2013-02-19 | semi-stationary balloon in the gastric antrum with anchor rod for weight loss induction in humans. | |
US7494459B2 (en) | 2003-06-26 | 2009-02-24 | Biophan Technologies, Inc. | Sensor-equipped and algorithm-controlled direct mechanical ventricular assist device |
US20060167334A1 (en) | 2003-06-26 | 2006-07-27 | Anstadt Mark P | Method and apparatus for direct mechanical ventricular actuation with favorable conditioning and minimal heart stress |
US7213961B2 (en) | 2003-07-11 | 2007-05-08 | Hubbell Incorporated | Low voltage luminaire assembly |
US20050015140A1 (en) | 2003-07-14 | 2005-01-20 | Debeer Nicholas | Encapsulation device and methods of use |
US7513867B2 (en) | 2003-07-16 | 2009-04-07 | Kardium, Inc. | Methods and devices for altering blood flow through the left ventricle |
US7735493B2 (en) | 2003-08-15 | 2010-06-15 | Atritech, Inc. | System and method for delivering a left atrial appendage containment device |
US9198786B2 (en) | 2003-09-03 | 2015-12-01 | Bolton Medical, Inc. | Lumen repair device with capture structure |
US7658748B2 (en) | 2003-09-23 | 2010-02-09 | Cardia, Inc. | Right retrieval mechanism |
PE20050438A1 (en) | 2003-10-20 | 2005-06-14 | Esperion Therapeutics Inc | PHARMACEUTICAL FORMULAS, METHODS AND DOSING REGIMES FOR THE TREATMENT AND PREVENTION OF ACUTE CORONARY SYNDROMES |
US20050085826A1 (en) | 2003-10-21 | 2005-04-21 | Scimed Life Systems, Inc. | Unfolding balloon catheter for proximal embolus protection |
US7824325B2 (en) | 2003-10-31 | 2010-11-02 | Corassist Cardiovascular Ltd. | In vivo for improving diastolic ventricular function |
WO2005046520A2 (en) | 2003-11-07 | 2005-05-26 | Mayo Foundation For Medical Education And Research | Device and method for treating congestive heart failure |
US20050187620A1 (en) | 2003-11-14 | 2005-08-25 | Suresh Pai | Systems for heart treatment |
US7566336B2 (en) | 2003-11-25 | 2009-07-28 | Cardia, Inc. | Left atrial appendage closure device |
US7381219B2 (en) | 2003-12-23 | 2008-06-03 | Sadra Medical, Inc. | Low profile heart valve and delivery system |
US20050228434A1 (en) | 2004-03-19 | 2005-10-13 | Aga Medical Corporation | Multi-layer braided structures for occluding vascular defects |
US7172551B2 (en) | 2004-04-12 | 2007-02-06 | Scimed Life Systems, Inc. | Cyclical pressure coronary assist pump |
US7695493B2 (en) | 2004-06-09 | 2010-04-13 | Usgi Medical, Inc. | System for optimizing anchoring force |
US8206417B2 (en) | 2004-06-09 | 2012-06-26 | Usgi Medical Inc. | Apparatus and methods for optimizing anchoring force |
US20050283218A1 (en) | 2004-06-22 | 2005-12-22 | Williams Michael S | Implantable chamber for biological induction or enhancement of muscle contraction |
AU2005286101A1 (en) | 2004-09-22 | 2006-03-30 | Corassist Cardiovascular Ltd. | In vivo device for assisting and improving diastolic ventricular function |
US20060079736A1 (en) | 2004-10-13 | 2006-04-13 | Sing-Fatt Chin | Method and device for percutaneous left ventricular reconstruction |
US8512350B2 (en) | 2004-12-01 | 2013-08-20 | Boston Scientific Scimed, Inc. | Single operator medical device handles and related methods of use |
US20060199995A1 (en) | 2005-03-02 | 2006-09-07 | Venkataramana Vijay | Percutaneous cardiac ventricular geometry restoration device and treatment for heart failure |
US7320665B2 (en) | 2005-03-02 | 2008-01-22 | Venkataramana Vijay | Cardiac Ventricular Geometry Restoration Device and Treatment for Heart Failure |
WO2006104143A1 (en) | 2005-03-28 | 2006-10-05 | Terumo Kabushiki Kaisha | Body organ expansion instrument |
US9034006B2 (en) | 2005-12-01 | 2015-05-19 | Atritech, Inc. | Method and apparatus for retrieving an embolized implant |
US8052715B2 (en) | 2005-12-01 | 2011-11-08 | Atritech, Inc. | Method and apparatus for recapturing an implant from the left atrial appendage |
EP1986735A4 (en) | 2006-02-06 | 2011-06-29 | Northwind Ventures | Systems and methods for volume reduction |
US8111044B2 (en) | 2006-03-03 | 2012-02-07 | Griffin Technology Inc. | Auxiliary power adapter having device controls |
US7837610B2 (en) | 2006-08-02 | 2010-11-23 | Kardium Inc. | System for improving diastolic dysfunction |
US20100274227A1 (en) | 2009-02-13 | 2010-10-28 | Alexander Khairkhahan | Delivery catheter handle cover |
-
2006
- 2006-12-14 US US11/640,469 patent/US7674222B2/en not_active Expired - Lifetime
-
2007
- 2007-12-13 JP JP2009541604A patent/JP5461192B2/en not_active Expired - Fee Related
- 2007-12-13 WO PCT/US2007/087497 patent/WO2008076853A2/en active Application Filing
- 2007-12-13 AU AU2007333895A patent/AU2007333895A1/en not_active Abandoned
- 2007-12-13 EP EP07865668A patent/EP2091588A4/en not_active Ceased
- 2007-12-13 CA CA002671974A patent/CA2671974A1/en not_active Abandoned
-
2010
- 2010-01-21 US US12/691,587 patent/US8672827B2/en not_active Expired - Fee Related
Non-Patent Citations (2)
Title |
---|
None |
See also references of EP2091588A4 |
Cited By (12)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US11406829B2 (en) | 2004-02-12 | 2022-08-09 | Backbeat Medical, Llc | Cardiac stimulation apparatus and method for the control of hypertension |
US11577059B2 (en) | 2005-03-02 | 2023-02-14 | Backbeat Medical, Llc | Methods and apparatus to increase secretion of endogenous naturetic hormones |
US11529520B2 (en) | 2006-09-25 | 2022-12-20 | Backbeat Medical, Llc | Methods and apparatus to stimulate heart atria |
US11083894B2 (en) | 2008-09-08 | 2021-08-10 | Backbeat Medical, Llc | Methods and apparatus to stimulate the heart |
US11759639B2 (en) | 2008-09-08 | 2023-09-19 | Backbeat Medical, Llc | Methods and apparatus to stimulate the heart |
JP2012505699A (en) * | 2008-10-20 | 2012-03-08 | コーアシスト・カーデイオバスキユラー・リミテツド | Ventricular assist device and method and apparatus for implanting it |
US10967188B2 (en) | 2012-12-21 | 2021-04-06 | Backbeat Medical, Llc | Methods and systems for controlling blood pressure by controlling atrial pressure |
US11097108B2 (en) | 2012-12-21 | 2021-08-24 | Backbeat Medical, Llc | Methods and systems for lowering blood pressure through reduction of ventricle filling |
US11452875B2 (en) | 2012-12-21 | 2022-09-27 | Backbeat Medical, Llc | Methods and systems for lowering blood pressure through reduction of ventricle filling |
US11712567B2 (en) | 2012-12-21 | 2023-08-01 | Backbeat Medical, Llc | Methods and systems for controlling blood pressure by controlling atrial pressure |
US11389658B2 (en) | 2015-09-11 | 2022-07-19 | Backbeat Medical, Llc | Methods and systems for treating cardiac malfunction |
US11426589B2 (en) | 2016-04-22 | 2022-08-30 | Backbeat Medical, Llc | Methods and systems for controlling blood pressure |
Also Published As
Publication number | Publication date |
---|---|
US20100121132A1 (en) | 2010-05-13 |
EP2091588A4 (en) | 2010-05-26 |
JP2010512855A (en) | 2010-04-30 |
CA2671974A1 (en) | 2008-06-26 |
US7674222B2 (en) | 2010-03-09 |
US8672827B2 (en) | 2014-03-18 |
JP5461192B2 (en) | 2014-04-02 |
US20070161846A1 (en) | 2007-07-12 |
EP2091588A2 (en) | 2009-08-26 |
AU2007333895A1 (en) | 2008-06-26 |
WO2008076853A3 (en) | 2008-10-02 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US7674222B2 (en) | Cardiac device and methods of use thereof | |
US10251750B2 (en) | Systems and methods for improving cardiac function | |
US7862500B2 (en) | Multiple partitioning devices for heart treatment | |
EP1781186B1 (en) | Ventricular partitioning device | |
US7399271B2 (en) | Ventricular partitioning device | |
JP4301501B2 (en) | In vivo method and apparatus for improving left ventricular diastolic function | |
US7762943B2 (en) | Inflatable ventricular partitioning device | |
US7582051B2 (en) | Peripheral seal for a ventricular partitioning device | |
US11752321B2 (en) | Non-blood contacting mechanical device that improves heart function after injury | |
WO2020214463A1 (en) | Fibrotic ventricular tissue disruption |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 07865668 Country of ref document: EP Kind code of ref document: A2 |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2007333895 Country of ref document: AU |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2671974 Country of ref document: CA |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2007865668 Country of ref document: EP |
|
ENP | Entry into the national phase |
Ref document number: 2009541604 Country of ref document: JP Kind code of ref document: A |
|
NENP | Non-entry into the national phase |
Ref country code: DE |
|
ENP | Entry into the national phase |
Ref document number: 2007333895 Country of ref document: AU Date of ref document: 20071213 Kind code of ref document: A |